

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 771 878 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

07.05.1997 Bulletin 1997/19

(51) Int. Cl.⁶: C12N 15/82, C12N 15/54,
A01H 5/00, A01H 5/10

(21) Application number: 95402425.3

(22) Date of filing: 31.10.1995

(84) Designated Contracting States:

GB

- Grootwassink, Jan Willem Derk
Saskatoon-Saskatchewan S7H 3A6 (CA)
- Underhill, Edward Wesley
Victoria-British Columbia V8V 2T4 (CA)
- Hemmingsen, Sean Mathias
Saskatoon-Saskatchewan S7H 3A2 (CA)
- Reed, Darwin Wilfred
Saskatoon-Saskatchewan S7M 4J9 (CA)
- Kolenovsky, Allan Dale
Saskatoon-Saskatchewan S7K 5C4 (CA)

(71) Applicants:

- PLANT GENETIC SYSTEMS N.V.
9000 Gent (BE)
- NATIONAL RESEARCH COUNCIL CANADA
Ottawa Ontario K1A 0R6 (CA)

(72) Inventors:

- Van Audenhove, Katrien
B-8310 Assebroek (Brugge) (BE)
- Peferoen, Marnix
B-9850 Nevele (BE)

(74) Representative: Desaix, Anne et al
Ernest Gutmann - Yves Plasseraud S.A.
3, rue Chauveau-Lagarde
75008 Paris (FR)

(54) Plants with reduced glucosinolate content

(57) The present invention relates to a method to reduce glucosinolate production and/or accumulation in plants wherein a reduced glucosinolate content is desired, particularly in the seeds of these plants. In accordance with the present invention, chimeric gene constructs inhibiting an enzyme responsible for glucosinolate production, the enzyme UDP-glucose:thiohydroximate S-glucosyltransferase (further referred to as "S-GT") are provided. Further in accordance with the present invention, plants are provided having substantially lower glucosinolate levels in their tissues, particularly in their seeds, which permit a significant expansion of the germplasm basis for the breeding of new oilseed rape varieties having lower glucosinolate levels, particularly in their seeds.

EP 0 771 878 A1

Description**Field of the invention**

5 The present invention relates to a method to reduce glucosinolate production and/or accumulation in plants wherein a reduced glucosinolate content is desired, particularly in the seeds of these plants. In accordance with the present invention, chimeric gene constructs inhibiting an enzyme responsible for glucosinolate production, the enzyme UDP-glucose:thiohydroximate S-glucosyltransferase (further referred to as "S-GT") are provided. Further in accordance with the present invention, plants are provided having substantially lower glucosinolate levels in their tissues, particularly in their seeds, which permit a significant expansion of the germplasm basis for the breeding of new oilseed rape varieties having lower glucosinolate levels, particularly in their seeds.

Background

15 Glucosinolates are low molecular weight sulphur-containing glucosides that are produced and stored in almost all tissues of members of the Capparales, the most important member being the group of Crucifer plants (Haughn et al., 1991, *Plant Physiol.* 97, 217-226). They are composed of two parts, a glycone moiety and a variable aglycone side chain derived from α -amino acids. When intact, these secondary metabolites are totally passive and innocuous, and do not have any known physiological function. During the mechanical breaking of plant tissues, e.g., during consumption, 20 the glucosinolates come into contact with an endogenous enzyme, myrosinase. The resulting breakdown products include isothiocyanates, nitriles, thiocyanates, isocyanates, thiones and alcohols. Intake of large amounts of glucosinolates and their breakdown products cause acute goiter and chronic disease in experimental and food-producing animals (Bell, 1993, *Can. J. Anim. Sci.* 73, 679-697).

25 From an agronomical point of view, the most important part of an oilseed rape crop are the seeds, which are used to extract the oil. The seed cake is a protein-rich animal feed, which remains after extraction of the oil from the seeds. The presence of glucosinolates in the seed cake is undesired in view of the known toxicity of glucosinolate-breakdown products on animals and humans. Certainly for oilseed crops such as mustard and oilseed rape, the presence of these 30 glucosinolate-breakdown products is problematic. Therefore, breeding programs have been set up to decrease the amount of glucosinolates in these crops, particularly in oilseed rape, to an acceptable level. Unfortunately, however, glucosinolate production in *Brassica napus* appears to be a multigenic trait.

In Canada, the term "canola" describes oilseed rape with limited levels of glucosinolates and erucic acid in the harvested seeds. Conventional plant breeding efforts have in exceptional cases already resulted in some "zero" glucosinolate oilseed rape varieties.

The cDNA sequence of a *B. napus* myrosinase, an enzyme breaking down glucosinolates, has been described (Falk et al., 1992, *Plant Science* 83, 181-186). It has been suggested to target the myrosinase to the storage sites of the glucosinolates in the plant cells so as to prematurely destroy them (GrootWassink, 1994a, PBI Bulletin (National Research Council of Canada)).

40 Furthermore, several attempts have been made to isolate a pure S-GT enzyme from several Crucifers, but these were not successful, since the S-GT enzyme occurs at very low levels, most of the activity is lost upon purification, the enzyme is instable and the enzyme tends to associate with other materials released from the cells (Reed et al. (*Arch. Biochem. Biophys.* 305, 526-532, 1993); Guo et al. (*Phytochemistry* 36, 1133-1138, 1994)). Although GrootWassink et al. (1994b, *Plant Physiol.* 105, 425-433) describe the immunopurification of S-GT from the florets of *Brassica oleracea* spp. *botrytis* (cauliflower), this method resulted in a protein containing several S-GT isoenzymes with different pI values. Thus, the purification to homogeneity of a sole S-GT enzyme has not been accomplished to date.

45 It has also been suggested to put the gene for the S-glucosyltransferase enzyme back into canola, but in reverse orientation so that the antisense DNA strand is transcribed (Poulton and Moller, 1993, In *Methods in Plant Biochemistry*, vol. 9. Academic Press, London, pp. 209-237; GrootWassink, 1994a, *supra*). However, this suggestion was never accomplished since the isolation or cloning of a DNA sequence encoding an S-GT enzyme has never been reported.

50 Chavadej et al. (1994, *Prot. National Acad. Science USA* 91, 2166-2170) expressed a tryptophan decarboxylase in transgenic oilseed rape plants to obtain a significant decrease in the levels of indole glucosinolates. However, the levels of other glucosinolates remained unaltered.

Accordingly, it is an object of the present invention to overcome the problems known in the art by providing a pure S-GT enzyme, the DNA sequence encoding it and a method to reduce glucosinolate production and/or accumulation in plants. These and other objects are achieved by the present invention as evidenced by the summary of the invention, description of the preferred embodiments and the claims.

Summary of the invention

Accordingly, it is an object of the present invention to provide a method for reducing the S-GT activity in plant cells,

by reducing the expression of the s-gt isoforms genes.

Yet another object of the present invention is to provide plant-expressible chimeric genes and transformation vectors comprising an s-gt inhibitory chimeric gene such as a gene encoding an antisense s-gt RNA. In a preferred embodiment, the present invention provides a plant expressible chimeric gene comprising a gene encoding an antisense RNA complementary to all or part of the RNA encoded by the plant s-gt gene, the cDNA of which is comprised in clone pGL9, which is deposited at the BCCM-LMBP under accession number 3344.

Yet another preferred embodiment of the present invention provides a chimeric gene encoding an antisense RNA complementary to all or part (at least 100 nucleotides) of the RNA, a cDNA of which comprises the DNA sequence of SEQ ID No. 28, or an antisense RNA complementary to the RNA encoded by a variant of the s-gt gene, coding for a protein with substantially the same S-GT activity, such as any of the DNA sequences represented in Figure 2.

In yet another aspect, the present invention provides a plant, transformed to contain a chimeric gene comprising :

- (a) a plant-expressible promoter ;
- (b) a transcribed region operably linked to said promoter, comprising a DNA sequence encoding an RNA or protein, wherein said RNA or protein interferes with the normal expression of the UDP-glucose:thiohydroximate S-glucosyl-transferase gene (s-gt gene) in cells of said plant; and
- (c) a 3' transcription termination and polyadenylation region active in said plant; as well as seeds, and seed cakes obtained from said seeds.

Yet another aspect of the present invention provides a DNA comprising a region encoding a protein with UDP-glucose:thiohydroximate S-glucosyltransferase activity, selected from the following:

- 1) a DNA encoding an mRNA, the cDNA of which is contained in plasmid pGL9, deposited in E. coli WK6 at the BCCM-LMBP under accession number 3344;
- 2) a DNA encoding an mRNA, the cDNA of which has the sequence of SEQ ID No. 28;
- 3) a DNA having substantial sequence homology to SEQ ID No. 28.

Yet another aspect of the present invention provides a DNA sequence encoding an antisense RNA selected from the following:

- 1) an antisense RNA which is complementary, preferably at least 90 % complementary, more preferably at least 95 % complementary, to a region of at least 100 nucleotides, preferably a region of at least 500 nucleotides, of an mRNA, the cDNA of which is contained in plasmid pGL9, deposited in E. coli WK6 at the BCCM-LMBP under accession number 3344;
- 2) an antisense RNA, which is at least 90 % complementary, more preferably at least 95 % complementary, to a region of at least 100 nucleotides, preferably a region of at least 500 nucleotides, of an mRNA, the cDNA of which comprises the coding region of SEQ ID No. 28; or
- 3) an antisense RNA encoded by the s-gt inhibitory gene contained in plasmid TKV8a included in E. coli, MC1061, deposited at the BCCM-LMBP under accession number LMBP 3343, or an RNA having substantial sequence homology thereto.

Yet another aspect of the present invention provides a process for obtaining a Brassica napus plant having a significantly reduced expression of an s-gt gene, comprising the following steps:

- a) transforming a plant cell with a s-gt inhibitory chimeric gene; and
- b) regenerating a plant from said transformed cell.

Also contemplated by the present invention are hybrid plants having a glucosinolate content of less than 30 µmoles per gram dry defatted seed glucosinolates in their seeds.

Brief Description of the Drawings

Fig.1 is a schematic representation of the different cDNA clones obtained from B. napus S-GT mRNA and their delineation on the full cDNA obtained. The thick lines represent the coding region, the thinner lines represent the 5' and 3' untranslated sequences of the cDNA. The primers used to obtain the cDNAs are indicated, with their corresponding direction ("ANCH" refers to the 5' or 3' Anchor primers (Clontech) described below, locations are approximate and the arrows representing the primers are not drawn to scale).

Fig. 2 is the ORF of the pGL9 clone of SEQ ID No. 28 indicating all nucleotide differences found in the coding regions of the different s-gt cDNAs isolated in accordance with this invention. The altered nucleotide in the coding

regions of the other cDNAs is indicated above the DNA sequence of the pGL9 clone, the corresponding nucleotide in the DNA sequence of pGL9 is in lowercase letters. The numbers between brackets are as follows: (6) refers to the pGL6-14 clone, (3) to pGL3-22, (4) to pGL4-2, (7) to pGL2-7, (25) to pGL2-25. The underlined parts were found to be identical between pGL18 clone 1 and the pGL9 clone. No amino acid differences are indicated in the Figure. The 5' and 3' ends of the open reading frames contained in the different cDNA clones are also shown above the pGL9 sequence by the marks < and >, respectively (the consecutive numberings refer to amino acid positions).

Detailed Description of the Preferred Embodiments of the Invention

The present invention provides a method to reduce glucosinolate production and/or accumulation in plants. This method was achieved by isolating DNA sequences encoding a *Brassica napus* S-GT enzyme form. Starting from the partial amino acid sequences of peptide fragments obtained from the purified *B. oleracea* S-GT, degenerate DNA primers were designed and DNA fragments encoding all or part of an S-GT enzyme were isolated by PCR-RACE.

The following definitions are provided to further clarify the terminology used throughout the specification, it being understood that these definitions are provided for the person skilled in the art to solely use as a basis for interpreting the preferred embodiments, the examples and the claims.

As used herein, "substantial sequence similarity", refers to DNA sequences encoding similar RNAs and/or proteins with some differences in their RNA or amino acid sequence, e.g., nucleotide or amino acid deletions, additions, or replacements, with the proviso that these similar RNAs and/or proteins still retain significantly the same function or activity. Preferably, DNA sequences with "substantial sequence similarity" encode proteins having the same tertiary structure in those domains or regions determining the protein activity. Also encompassed in the definition of "substantial sequence similarity", when referring to DNA sequences, are different DNA sequences encoding the same proteins. Indeed, because of the degeneracy of the genetic code, many different DNA sequences can encode one protein. Also, during cloning work some nucleotides can be changed to create suitable restriction sites throughout a DNA sequence, or introns can be inserted, while retaining substantial sequence similarity. These nucleotide changes made during cloning are also encompassed by the term "substantial sequence similarity".

Furthermore, natural variants having substantial sequence similarity to a DNA sequence differing in some nucleotides or synthetic variants having substantial sequence similarity which can be made by recombinant DNA techniques are encompassed by the definition of "substantial sequence similarity".

In a preferred embodiment of this invention, DNA sequences have substantial sequence similarity if they have more than 85 %, preferably more than 90 %, more preferably more than 95 %, sequence similarity.

Sequence similarity between two nucleotide sequences is conveniently measured by the Wilbur and Lipmann algorithm with the IntelliGenetics™ (Intelligenetics Inc.) sequence analysis package (Wilbur and Lipmann, 1983, Proc. Natl. Acad. Sci. USA 80, 726) using a window-size of 20 nucleotides, a word length of 4 nucleotides and a gap penalty of 4.

It is known that some amino acids in a protein can be replaced by others, provided the tertiary structure is not significantly altered. Therefore, for proteins, "substantial sequence similarity" refers to proteins differing in some amino acids, e.g., by amino acid deletions, additions or replacements, while retaining the same overall function as determined by the proteins tertiary structure. Typically, amino acid differences between functionally active protein forms with substantial sequence similarity are below 5 %, preferably below 3 %, of the total number of amino acids. Sequence similarity between two protein sequences can be conveniently measured by the Wilbur and Lipmann algorithm with the IntelliGenetics™ (Intelligenetics Inc.) sequence analysis package (Wilbur and Lipman, 1983, *supra*) using a window size of 20 amino acids, a word length of 2 amino acids, and a gap penalty of 4.

A "chimeric gene", as used herein, is a gene wherein at least one regulatory region is heterologous to and therefore not normally associated with the coding region or the transcribed region in nature; e.g., an *s-gt* coding region under the control of a bacterial promoter.

As used herein, "a plant-expressible chimeric gene" is a gene expressible in cells of a plant, comprising at least one regulatory region; e.g., a plant-expressible promoter or a 3' transcription termination and polyadenylation sequence active in plant cells, which is not normally associated with the transcribed region or the coding region in plant cells in nature. A plant-expressible chimeric gene in accordance with this invention typically encodes an RNA which is translated into a protein, or an RNA which is functional as such, e.g., an antisense RNA or a ribozyme. A DNA encoding an (antisense) RNA, complementary to a (sense) RNA produced in a plant cell, operably linked to the promoter and 3' transcription termination and polyadenylation region normally regulating transcription of the (sense) RNA, is also included under the definition of chimeric gene in accordance with this invention.

As used herein, "plant-expressible promoter" is a promoter active in plant cells, including but not limited to promoters of plant origin and of bacterial or viral origin that are functional in plant cells (e.g., CaMV 35S promoter, *Agrobacterium* T-DNA promoters and the like).

As used herein, "promoter" is a nucleotide sequence recognized (directly or indirectly) and bound by DNA-dependent RNA polymerase during initiation of transcription.

As used herein, "promoter region" is a DNA sequence typically located 5' of a coding region, and including the pro-

moter and a 5' untranslated leader sequence.

As used herein, "transcribed region" is that region of a DNA transcribed into an RNA, typically comprising 5' leader sequences, a coding region (which, by definition includes a region encoding a protein or a region encoding an antisense RNA or a ribozyme) and 3' untranslated trailer sequences.

5 As used herein, "antisense RNA" is an RNA molecule which, by binding to (hybridizing to) a complementary sequence in another nucleic acid molecule (RNA or DNA), inhibits the function and/or completion of synthesis of the complementary molecule. Antisense RNA is typically produced from a chimeric gene by operably linking all or part of a DNA sequence encoding an RNA sequence to a promoter in the orientation opposite to the orientation in which the DNA encoding the RNA (or its part) is operably linked to its promoter in an endogenous plant gene, so that an RNA is formed which is complementary to all or part of the RNA normally produced from the endogenous gene in a plant cell. 10 Antisense RNA can comprise a sequence complementary to all or part of the 5' and 3' untranslated regions of an RNA to be inactivated, or even a sequence complementary to introns or parts of introns of a pre-mRNA, such that the anti-sense is rendered more specific. The antisense RNA is at least 85 %, preferably at least 90 %, most preferably 95 to 100 %, complementary to the RNA to be inhibited.

15 The term "complementary", as used herein, refers to a sequence of nucleotide bases in one strand of a DNA or RNA molecule that is exactly complementary to that on another single strand such that there is no variation between the adenine-thymidine, adenine-uracil or guanine-cytosine base pairs.

20 As used herein, "90 % complementary" refers to an RNA sequence wherein 90 % of the nucleotides are complementary to the corresponding nucleotides in another RNA sequence, preferably of the same length, so that only 10 % of the nucleotides will not hybridize to the corresponding nucleotide on the other RNA or DNA. For example, for two RNAs with the same number of nucleotides, when RNA sequence 1 is 90 % complementary to an RNA sequence 2, the complementary form of RNA sequence 1 will have 90 % sequence similarity with RNA sequence 2.

25 "S-GT", or "S-GT protein" as used herein, refers to a member of the UDP-glucose:thiohydroximate S-glucosyltransferase enzyme family (EC 2.4.1.-) of plants, particularly Brassica plants, that comprises the enzyme forms which catalyze the penultimate step in glucosinolate production.

"s-gt gene" or "s-gt DNA", as used herein, refers to a DNA sequence encoding an S-GT protein.

30 As used herein, "functionally equivalent parts" of a DNA, RNA or protein are portions of a DNA, RNA or protein which have the same function or activity as the full DNA, RNA or protein. For example, a functionally equivalent part of an antisense RNA, is a portion of an antisense RNA, wherein this portion exhibits substantially the same antisense (inhibitory) effect as the full length antisense RNA, although the portion will differ from the full length antisense RNA in certain other characteristics such as molecular weight, its size, its relative nucleotide composition and the like. Also, a protein fragment, which has the same metabolic activity (e.g., glucosyltransferase activity in plant cells) as the entire protein, is a "functionally equivalent part" of that protein in accordance with this invention.

35 As used herein, "gene silencing" is a significant or complete reduction in detectable gene expression. Gene silencing can be achieved at any level of gene expression, and results in a significant drop of production of RNA or protein. In a preferred embodiment, gene silencing is achieved by using a DNA encoding an antisense RNA or a functionally effective part thereof.

40 As used herein, "partial gene silencing" refers to an inhibition of expression of less than 100 %, preferably from about 50 to about 95 %, as measured by RNA or protein levels, while "complete gene silencing" refers to the situation wherein no detectable gene expression (RNA or protein) is observed.

45 As used herein, a "ribozyme" is a catalytic RNA molecule capable of specifically cleaving another RNA. A ribozyme typically has a "targetting" sequence which is complementary to another RNA, so that the ribozyme can recognize and cleave this other RNA. The targetting sequence preferably is at least 90 %, more particularly at least 95 %, preferably 100 %, complementary to the RNA which is to be cleaved.

50 As used herein, the terms "significantly reduced", "significant inhibition", or "significantly lower levels", when referring to s-gt gene expression, refer to a quantitative difference in expression of the native s-gt gene in a plant cell transformed with an s-gt inhibitory chimeric gene when compared to the situation in the wild-type plant, as is evidenced by protein levels measured via quantitative protein assays (e.g., ELISA), in a plant cell. Preferably, significantly reduced or inhibited expression of an s-gt gene in accordance with this invention refers to a reduction in formation of S-GT protein of 50% to 95%, particularly at least 75%, more particularly at least 85%, preferably 95%, in a plant cell as is measured by protein quantitative assays in comparison to a cell of the same cell type used as a control, or by s-glucosyl transferase activity as measured by GrootWassink et al, 1994b *supra*.

55 "Reduced total glucosinolate", as used herein, refers to a reduction in total glucosinolate levels to below 30 µmoles per gram oil free seed matter, preferably below 10, more preferably below 5 µmoles per gram oil free seed matter, particularly to undetectable levels using the method of GrootWassink et al (1994b).

In accordance with this invention, DNA sequences encoding S-GT proteins have been isolated. All or part of the isolated s-gt DNA, preferably the s-gt coding region, can be used in a variety of ways, including but not limited to the production of S-GT protein in bacteria, the use of the isolated s-gt DNA in chimeric genes, plants transformed by the chimeric genes according to the invention, the production of seeds lacking or having reduced content of glucosinolates

and the production of seed cakes obtained by the crushing of the seeds.

To produce S-GT protein free from contaminating plant proteins, all or part of the isolated s-gt DNA and preferably the s-gt coding region can be used. Preferred promoter and 3' transcription termination sequences for the chimeric s-gt gene to be expressed in bacteria are derived from bacterial genes (see, Sambrook et al, Molecular Cloning. A Laboratory Manual (1989)). The s-gt cDNA which corresponds to the full open reading frame of an s-gt gene (and which is contained in plasmid pGL9 (BCCM-LMBP 3344)), is cloned into an E. coli expression vector, by methods known in the art, to recombinantly produce the protein. The activity of the recombinantly produced S-GT enzyme is confirmed by assaying for glucosyl-transferase-activity using the assay as described by Reed et al. (1993, supra) and GrootWassink et al. (1994b, supra).

A DNA sequence encoding a B. napus S-GT enzyme as shown in SEQ ID No 28. Nevertheless, other different isoforms of the gene exist, having some amino acids differences. Some amino acids were found to be different in the B. napus clone when compared to the peptide fragments obtained from the B. oleraceae S-GT form. It is clear from the Examples and from Figure 2, that also in B. napus, evidence for the existence of isozymes differing in some amino acid residues was found. This indicates that a small family of related s-gt genes having substantial sequence similarity exists in Brassica plants.

The following amino acids were found to be different between the S-GT protein of SEQ ID No. 28, the B. oleraceae protein and the other isoforms, of which a cDNA clone was isolated. The amino acid which is different at this position in an isoform, and, between brackets, the amino acid in SEQ ID No. 28 as indicated below; position 2: Val(Ala); between position 10-11: add Lys between amino acids 10 and 11; position 12: Ser(Asn); position 43: Leu(Val); position 75: Pro(Leu); position 88: Gly(Glu); position 93: His(Asn); position 96: Gln(Glu); position 133: Leu(Ile); position 153: Ala(Val); position 167: Leu(Pro); position 204: Ile(Arg); position 216: Gly(Ser); position 232: Thr(Ala); position 234: Lys(Arg); position 243: Asp(Pro); position 249: Ala(Gly); position 290: Arg(Gly); position 302: Thr(Lys); position 319: Arg(His); position 350: Gly(Val); position 350: Glu(Val); position 395: Lys(Arg); position 402: Asp(Glu); position 419: Lys(Arg).

Therefore, preferred S-GT proteins of the invention include variants of the protein of SEQ ID No. 28 having at least one of the above amino acids in the protein of SEQ ID No. 28 changed into another amino acid indicated in the above list.

Preferably, Cysteine amino acids are not altered in S-GT enzymes having substantial sequence similarity to the S-GT form encoded by the cDNA contained in clone pGL9, since SH-bonds are believed to be involved in enzymatic activity. Also, preferred s-gt DNA's or coding regions in accordance with this invention are those DNA sequences encoding the S-GT variants, having at least one of the above amino acid substitutions. A functionally equivalent variant or part of the S-GT enzyme of SEQ ID No:28, in accordance with this invention, is an enzyme having at least 80 %, preferably at least 90 %, of the activity of this S-GT enzyme (SEQ ID No:28) using the glucosyltransferase radioassay of GrootWas-sink et al. (1994b, supra), when analyzed under the same test conditions.

Furthermore, given the DNA sequence of the isolated S-GT form, variants can be designed having a different codon usage or containing additional untranslated sequences such as introns but encoding the same protein or a protein having substantial sequence similarity. Also, based on the amino acid sequence of the protein encoded by the cDNA comprised in clone pGL9, variants can be made differing in some amino acids but having substantially the same glucosyltransferase activity. Upon initial comparison of the protein primary structure with other plant glucosyltrans-ferases, particularly the protein parts from amino acids 16-42, 180-185, 346-375, 448-453 in SEQ ID No. 28 should be preferentially retained when designing variants of the B. napus S-GT enzyme. Therefore, amino acid substitutions in these regions should be kept to minimal (e.g., no more than 10 %, preferably no more than 5 %) in order to retain most of the S-GT activity.

In a preferred embodiment of this invention, DNA sequences with substantial sequence similarity to the s-gt DNA of the invention include DNA sequences encoding the protein produced by plasmid pGL9 contained in E. coli WK6, deposited in accordance with the Budapest Treaty at the BCCM-LMBP on September 7, 1995 under accession number 3344.

Variants of the S-GT enzyme can be isolated based on the knowledge of the protein peptidic fragments of the B. oleraceae S-GT enzyme of the invention. A S-GT enzyme variant of the present invention should retain the enzyme's catalytic site and thus are characterized by their clear S-GT activity in the radioassay of Reed et al. (1993, supra) and the presence of a continuous stretch of amino acids with more than 85 % sequence similarity, particularly more than 90 % sequence similarity, preferably more than 95 % sequence similarity, to any one of the peptide fragments 1 to 7 of SEQ ID Nos. 1 to 7. Preferentially variants of the S-GT enzyme of this invention have S-GT activity and comprise any of the peptides of SEQ ID Nos 1 to 7, preferably the peptide of SEQ ID No. 1, in their primary sequence. Since it was found that none of the peptides of SEQ ID Nos 1 to 7 are found in any known protein, the presence of any of these peptides in a protein sequence having glucosyltransferase activity characterizes the S-GT protein of the invention.

Generally in accordance with the present invention, s-gt inhibitory chimeric genes are provided for plant transformation. As used herein, "s-gt inhibitory chimeric gene" is a chimeric gene comprising all or part of a coding sequence encoding an RNA or protein inhibiting s-gt gene expression. For example, a chimeric gene of the present invention

includes all or part of a DNA encoding an antisense RNA, a sense RNA, or a ribozyme, inhibiting s-gt gene expression when produced in a plant cell. The specific coding region of an s-gt inhibitory chimeric gene typically also comprises, besides a coding region, a promoter region, a coding region, and a 3' transcription termination and polyadenylation region.

5 Any plant expressible promoter can be used to express the inhibitory chimeric gene of the present invention.

Preferred plant-expressible promoters of the s-gt inhibitory chimeric gene of this invention include, but are not limited to : the strong (constitutive) 35S promoters (the "35S promoters") of the cauliflower mosaic virus of isolates CM 1841 (Gardner et al., 1981, Nucleic Acids Research 9, 2871-2887), CabbB-S (Franck et al., 1980, Cell 21, 285-294) and CabbB-JI (Hull and Howell, 1987, Virology 86, 482-493); the ubiquitin promoter (EP 0342926), and the TR1' promoter and the TR2' promoter which drive the expression of the 1' and 2' genes, respectively, of the Agrobacterium tumefaciens T-DNA (Velten et al., 1984, EMBO J. 3, 2723-2730).

10 Alternatively, a promoter can be utilized which is not constitutive but rather is specific for one or more tissues or organs of the plant, such as the pod tissue, whereby the inserted chimeric s-gt inhibitory gene or its functionally effective part is expressed only in cells of the specific tissue or organ. Since it has been shown that the important glucosinolates stored in the seed are derived from the adjacent pod tissue, particularly from the pod walls (Toroser et al, 1995, Annual Meeting of the American Society of Plant Physiologists, Charlotte, North Carolina, July 29-August 2, USA, in Supplement to Plant Physiology, vol. 108, abstract 716), a plant-expressible promoter can be utilized which is at least expressed in pod tissue, and particularly in the pod wall; preferably highly expressed in pod tissue, more preferably the pod wall. Pod tissue-specific promoters as used here include the promoters of the genes encoding pod-specific 15 mRNAs, e.g., the promoters of the genes encoding the mRNAs reported by Coupe et al. (1993, Plant Mol. Biol. 23, 1223; 1994, Plant Mol. Biol. 24, 223).

20 For example, preferential expression in the pod tissue by a pod tissue-specific promoter, preferably in the pod wall (e.g., the carpels constituting the pod wall) by a pod-wall-specific promoter is an alternative method to lower seed glucosinolate levels without interfering, to a large extent, with the glucosinolate content of the leaves and other tissues, which may be more desirable in certain circumstances.

25 "Pod tissue", as used herein, refers to the cells constituting a pod, including structures such as the carpels forming the pod wall, the (false) septum, and the replum but excluding the seeds.

30 In yet another embodiment of the present invention, the promoter for the s-gt inhibitory chimeric gene of the invention can also be the promoter of the endogenous s-gt gene, the mRNA of which corresponds to the cDNA contained in plasmid pGL9, or can be a leaf-specific, stem-specific and in some cases even an embryo- or seed-specific promoter.

35 In accordance with this invention, the s-gt inhibitory chimeric gene, or a functionally effective part thereof, is inserted in the plant genome such that the inserted coding region is upstream (i.e., 5') of suitable 3' transcription termination and polyadenylation signals (i.e., transcript termination and polyadenylation signals). Preferred polyadenylation and transcript formation signals include but are not limited to those of the 35S gene (Mogen et al., 1990, The Plant Cell 2, 1261-1272), the octopine synthase gene (Gielen et al., 1984, EMBO J 3, 835-845) and the T-DNA gene 7 (Velten and Schell, 1985, Nucl. Acids Res. 13, 6981-6998), which act as 3'-untranslated DNA sequences in transformed plant cells. Alternatively, the 3' transcription termination and polyadenylation signals can be obtained from a pod tissue or pod wall 40 specific gene or from a plant s-gt gene.

More specifically, the coding region of the s-gt inhibitory chimeric gene of the invention comprises a DNA encoding 45 an RNA or protein interfering with the normal expression of the s-gt gene in the plant cell. A preferred coding region in accordance with this invention comprises a DNA sequence encoding an s-gt antisense RNA, or functionally effective variants thereof. In accordance with this invention, "s-gt antisense RNA" is an RNA complementary to at least part, preferably a functionally effective part, of the RNA, particularly the mRNA, encoded by an endogenous plant s-gt gene. For example, an RNA complementary to a region of at least 100 nucleotides, preferably a region of at least 500 nucleotides, 50 of the (m)RNA encoded by the s-gt gene, the cDNA of which is contained in pGL9 (deposited at the BCCM-LMBP under number LMBP 3344) can be utilized. An RNA complementary to a region of at least 100 nucleotides, preferably a region of at least 500 nucleotides, of the (m)RNA encoded by the s-gt gene, the cDNA of which has the sequence illustrated in SEQ ID No. 28 is encompassed by the present invention. Similarly, as described above for the s-gt DNA sequence, variants of the s-gt antisense RNA can be made, provided they have sufficient complementarity, more preferably at least 90 % complementarity, particularly at least 95 % complementarity, to the s-gt RNA formed in the plant cell.

Surprisingly, it was found that there are several isoform DNAs of the invention which have substantial sequence similarity, so one s-gt antisense RNA will be able to inhibit expression of all isoform genes. The antisense technology is based on blocking the information flow (by transcription and translation) from DNA to RNA and/or protein by the introduction of an RNA strand ("antisense RNA") complementary to the sequence of an endogenous target ("sense") RNA 55 (Murray & Crockett, 1992, in Antisense RNA and DNA, pp. 1-50, Murray, JAH (ed.), Wiley-Liss, New York). The outcome of this is a partial to complete silencing of endogenous gene expression (see, e.g., EP 0 467 349; EP 0 223 399; EP 0 240 208).

It has been shown that even the most abundant protein present in plants can be reduced effectively using antisense techniques (Rodermel et al., 1988, Cell 55, 673; Jiang et al., 1994, Plant Mol. Biol. 25, 569-576). The antisense RNA

can be complementary to only part of the (m)RNA transcribed from the gene that is to be inactivated. Preferably, such a part is at least about 100 basepairs long, more preferably at least about 500 basepairs long, typically between about 500-1000 basepairs long. Also, an antisense RNA which is complementary to the full (m)RNA to be inactivated, or to only the 5' and 3' untranslated regions, can be used.

In view of the down-regulation desired, the antisense RNA can be complementary to certain stretches of conserved sequences or to the most divergent sequences between the different s-gt RNA forms. Hence, the expression of a specific s-gt isoform, or of several isoforms sharing a conserved region, can also be inhibited. For isoform-specific inactivation of the s-gt gene, the 5' leader and 3' trailer sequences will be more useful target sequences, since it has been shown in the present invention that the S-GT isoform DNAs differ most in these regions, while differences in the coding region are limited. When different antisense RNAs can be used, it is preferred to use the antisense RNA which is most stable in the plant cell, particularly in the nucleus.

A preferred antisense construct of this invention is a construct comprising a DNA sequence encoding an RNA which is complementary, preferably 90% to 100% complementary, to at least 100 nucleotides of the RNA encoded by the s-gt gene, the mRNA of which corresponds to the cDNA sequence contained in plasmid pGL9 (deposited in host organism E. coli WK6 under accession number BCCM-LMBP 3344). It is more preferable to utilize a DNA sequence encoding an RNA which is complementary, preferably 90% to 100% complementary, to at least 100 nucleotides up to the entire mRNA sequence encoded by the s-gt gene, wherein a cDNA prepared from this mRNA has the sequence shown in SEQ. ID No. 28, or has substantial sequence similarity to the sequence of SEQ ID No. 28.

Preferred DNA sequences encoding an antisense s-gt RNA, in accordance with this invention, include DNA sequences encoding those RNAs hybridizing under stringent conditions with the (m)RNA (or parts thereof) encoded by the s-gt gene in a plant cell. This antisense RNA is at least 80 %, more particularly at least 90 %, more preferably at least 95 % complementary to the s-gt (m)RNA, particularly the s-gt mRNA, the cDNA of which is contained in plasmid pGL9 (BCCM-LMBP 3344). Indeed, it has been shown that for antisense inhibition of gene expression, 100 % complementarity is not required, however the antisense RNA has to be sufficiently complementary to the sense RNA so that they can readily hybridize under stringent conditions. This way, an entire gene family having high sequence similarity can be inhibited by expressing one antisense RNA which is 100 % complementary to one of the members of the gene family (see, e.g., Rodermel et al., 1988, supra).

In a further embodiment of this invention, the coding region of the chimeric s-gt inhibitory gene encodes a sense RNA which is identical, preferably has more than 80 % sequence similarity, more preferably has more than 90 % sequence similarity, most preferably has at least 95 % sequence similarity, to at least part of the (m)RNA transcribed from the gene, the cDNA of which corresponds to the DNA sequence contained in plasmid pGL9, preferably the cDNA with the sequence of SEQ ID No. 28, or functionally effective parts thereof. Similarly as for the antisense approach, a 5' or 3' part of the coding region, the full coding region as well as the 5' or 3' untranslated regions or the intron sequences can be used for gene silencing. Although antisense suppression is the preferred embodiment of this invention, the sense suppression (or cosuppression) mechanism (Flavell et al., 1994, Proc. Natl. Acad. Sci. USA 91, 3490-3496) can also yield plants having significant inhibition of s-gt gene expression in selected transformants.

Alternatively, the coding region of the chimeric s-gt inhibitory gene comprises a DNA sequence encoding a catalytic RNA molecule called a ribozyme (PCT publication WO 89/05852; Nature 334, 585-591, 1988), comprising a targeting region which is complementary, preferably 90% to 100% complementary, to part of the RNA formed by an s-gt gene, the mRNA of which corresponds to the cDNA contained in plasmid pGL9, or functionally effective variants thereof. The use of ribozymes allows the targeting of conserved or divergent RNA sequences, such that the expression of a group of S-GT isoforms (sharing a conserved region) or a particular S-GT isoform can be inhibited. Similarly, the EGS technology (e.g., PCT patent publication WO 93/22434) can be used to specifically inactivate s-gt gene expression.

The chimeric s-gt inhibitory gene can also encode an RNA encoding a protein inhibiting S-GT activity, such as an antibody fragment specifically binding to an S-GT, particularly the S-GT encoded by the DNA sequence comprised in clone pGL9, contained in E. coli WK6 (BCCM-LMBP 3344), more preferably the S-GT with the amino acid sequence of SEQ ID No. 28. Such antibodies or the Fab fragments thereof with high affinity to the S-GT protein isolated from clone pGL9 can be expressed in plants (Tavladoraki et al., 1993, Nature 366, 469-472), so that the endogenous S-GT protein is rendered inactive.

Since the S-GT enzyme was found to be non-specific for the side chain of the glucosinolate produced (Jain et al., 1988, J. Plant Physiol. 136, 356-361) the concentrations of all glucosinolates, and not just one type, normally produced in the plant, will be lowered when expressing a chimeric s-gt inhibitory gene, preferably a DNA sequence encoding an s-gt antisense RNA, in plants.

In order to transfer all or a functionally effective part of a chimeric s-gt inhibitory gene to a plant cell genome, suitable restriction sites can be introduced, flanking the chimeric gene or its part. This can be done by site-directed mutagenesis, using well-known procedures (e.g., Stanssens et al., 1989, Nucl. Acids Res. 12, 4441-4454; White et al., 1989, Trends in Genet. 5, 185-189).

In another embodiment of the invention, plant cells are transformed with the above chimeric genes, and plants are regenerated from such transformed cells. A disarmed Ti plasmid, containing the chimeric s-gt inhibitory gene, in Agro-

bacterium tumefaciens can be used to transform the plant cell, and thereafter, a transformed plant can be regenerated from the transformed plant cell using the procedures described, for example, in EP 0116718, EP 0270822, PCT publication WO 84/02913 and EP 0242246 (which are also incorporated herein by reference), and in Gould et al. (1991, Plant Physiol. 95, 426-434), or the method described in PCT publication WO 94/00977. Of course, other types of vectors can be used to transform the plant cell, using procedures such as direct gene transfer (as described, for example, in EP 0233247), pollen mediated transformation (as described, for example, in EP 0270356, PCT publication WO 85/01856, and US Patent 4,684,611), plant RNA virus-mediated transformation (as described, for example, in EP 0067553 and US Patent 4,407,956), and liposome-mediated transformation (as described, for example, in US Patent 4,536,475).

10 A resulting transformed plant, such as a transformed oilseed rape plant, can be used in a conventional plant breeding scheme to produce more transformed plants with the same characteristics or to introduce the chimeric s-gt inhibitory gene in other varieties of the same or related plant species or into commercial hybrid plants. Seeds, which are obtained from the transformed plants, contain the chimeric s-gt inhibitory gene as a stable genomic insert.

15 The preferred plants to be transformed in accordance with this invention include but are not limited to Crucifer plants, particularly Brassica plants, preferably oilseed rape Brassica plants, more preferably Brassica napus plants. The plants of the invention are characterized by their significantly lower levels of expression of the endogenous s-gt gene, preferably these plants are characterized by the lower glucosinolate content in their tissues, particularly in their seeds.

20 Hybrid plants, in accordance with this invention, can be made by crossing a transformed plant of the invention, homozygous for the s-gt inhibitory gene, with a male sterile plant, wherein the male sterile plant preferably is obtained by following the method described in EP 344029 and by Mariani et al. (1990, Nature 347, 737-741; 1992, Nature 357, 384-387).

25 In yet another preferred embodiment of the invention, the obtained hybrid plants containing the chimeric s-gt inhibitory gene correspond to the "canola" definition set out by the Canola Council of Canada. For oilseed rape to be designated "canola", oil obtained after crushing the seed has to contain less than 2 % of total fatty acids in the oil as erucic acid and less than 30 μ moles of alkenyl glucosinolates per gram of dry matter of the (oil-free) seed meal. Therefore, the eventual hybrid plants obtained in accordance with this invention preferably have a content of alkenyl glucosinolates, 30 preferably total glucosinolates, of less than 30 μ moles, preferably less than 15 μ moles, more preferably less than 5 μ moles per gram defatted dry matter of the seed. In the most preferred embodiment of this invention, the plants contain less than 0.5 μ moles total glucosinolates, preferably alkenyl glucosinolates, per gram dry matter of defatted seed, when the plants are hemizygous for the introduced chimeric s-gt inhibitory gene.

30 In yet another preferred embodiment of this invention, those tissues or organs of the plant other than pods or seeds can still contain their "wild-type" glucosinolate content. However, the total glucosinolate content, preferably the alkenyl glucosinolate content, in the entire plant is reduced to the above cited levels, preferably to undetectable levels.

35 Tentatively, promoters specific for leaves or other plant tissues or organs can be used to lower the glucosinolate content in these specific tissues or organs while maintaining the "wild-type" glucosinate levels in other parts of the plant.

40 In a preferred embodiment of this invention, the glucosinolate content in the plants, preferably in the seeds, is significantly decreased in hybrids, obtained from cross-fertilization of two parent plants, at least one of which has been transformed to inhibit s-gt gene expression in accordance with this invention. Further in accordance with this invention, the total glucosinolate levels in the seed of a hybrid Brassica plant, obtained in accordance with the teachings of the present invention, both parents of which contain less than 30 μ moles of alkenyl glucosinolates per gram dry defatted seed matter, is reduced. Preferably, hybrid plants are provided, wherein at least one of the parents has total glucosinolate levels of more than 30 μ moles, preferably more than 50 μ moles, per gram dry defatted seed and contains less than 30 μ moles of alkenyl glucosinolates per gram of defatted seed matter. Even more preferably, hybrid plants are provided, wherein at least one of the parents has total glucosinolate levels of more than 5 μ moles, preferably more than 50 μ moles, per gram in the defatted seed meal, and contains total glucosinolate levels in the whole seed basis of less than 5 μ moles per gram. Most preferably, hybrid plants are provided, from which at least one of the parents has glucosinolate levels above 0 μ moles (is the background levels found in the controls), preferably above 50 μ moles, and has no detectable glucosinolates in the seeds (0 μ moles).

45 In a further embodiment of this invention, a process is provided for inhibiting expression of an s-gt gene in a plant cells, particularly a process for lowering glucosinolate levels in plants, particularly Brassica plants. This process comprises the steps of transforming plant cells, preferably Brassica plant cells, with any of the above chimeric inhibitory s-gt genes, and then regenerating a plant from these transformed cells.

50 In yet another preferred process of the invention, plant cells are transformed with a DNA sequence encoding an antisense RNA complementary to at least part of the (m)RNA transcribed from the s-gt gene, particularly a DNA sequence encoding an antisense RNA complementary to the RNA, the cDNA of which is contained in plasmid pGL9; more particularly a DNA sequence encoding an mRNA, the cDNA of which comprises the sequence of SEQ ID No. 28 or a DNA sequence having substantial sequence similarity thereto.

55 Several assays are available for measuring both total and individual glucosinolates in plants or parts thereof (e.g., Quinsac and Ribbailler, 1991, Assoc. Off. Anal. Chem. 74, 932-939; Reed et al., 1993, supra). Depending on the desired

characteristics of the obtained plants, total glucosinolates or only glucosinolates of one type, preferably alkenyl glucosinolates, can be measured so that those plants with a reduced total glucosinolate content or with a reduced content in a certain type of glucosinolates, preferably alkenyl glucosinolates, can be selected after transformation. In accordance with this invention, the concentration of all glucosinolates formed by the S-GT enzyme, particularly the concentration of all alkenyl glucosinolates, is significantly lowered in the plants of the invention, preferentially in their seeds.

Since it is expected that other Cruciferous plants, particularly other Brassicaceae, have similar S-GT enzyme forms, differing in some characteristics but sharing regions with substantial sequence similarity, the antisense, ribozyme or co-suppression approaches outlined above can similarly be applied to lower the glucosinolate content in other Brassica species, preferably oilseed Brassica species. Preferred Brassicaceae to be transformed in accordance with this invention to inhibit s-gt expression, preferably to decrease glucosinolate content in the seed, besides Brassica napus, include Brassica juncea, Brassica oleracea, Brassica carinata, Brassica nigra, Brassica campestris and the like, and any intergenic crosses or synthetic varieties thereof.

In yet another preferred embodiment of this invention, the chimeric s-gt inhibitory gene is designed such that it effectively inhibits S-GT isoforms of both B. napus and B. juncea, so that glucosinolate production by genes of both parent genomes of these amphidiploid species is inhibited.

The thus obtained plants with lowered glucosinolate content, particularly in their seeds, are then used to cross into elite allele lines, preferably hybrid plants. Therefore, the effect of glucosinolate-reduction should preferably be apparent in the hemizygous state. In certain cases, two parent plants, transformed in accordance with this invention to have a lower glucosinolate content, particularly in their seeds, can be crossed to form a hybrid having a further reduced glucosinolate content. The following Examples are offered by way of illustration and not by way of limitation. The sequence listing referred to in the Examples is as follows:

SEQ ID No. 1:	<u>B. oleracea</u> S-GT peptide fragment 1
SEQ ID No. 2:	<u>B. oleracea</u> S-GT peptide fragment 2
SEQ ID No. 3:	<u>B. oleracea</u> S-GT peptide fragment 3
SEQ ID No. 4:	<u>B. oleracea</u> S-GT peptide fragment 4
SEQ ID No. 5:	<u>B. oleracea</u> S-GT peptide fragment 5
SEQ ID No. 6:	<u>B. oleracea</u> S-GT peptide fragment 6
SEQ ID No. 7:	<u>B. oleracea</u> S-GT peptide fragment 7
SEQ ID No. 8:	primer gl3
SEQ ID No. 9:	primer gl7
SEQ ID No. 10:	3' RACE oligo(dT) CDS primer sequence
SEQ ID No. 11:	3' RACE Anchor primer sequence
SEQ ID No. 12:	primer gl5
SEQ ID No. 13:	primer gl9
SEQ ID No. 14:	sequence of cDNA clone pGL2-7 (incorporated primer regions have not been added, part of polyA tail is shown)
SEQ ID No. 15:	sequence of cDNA clone pGL2-25 (incorporated primer regions have not been added, part of polyA tail is shown)
SEQ ID No. 16:	primer gl1
SEQ ID No. 17:	primer glP1
SEQ ID No. 18:	primer glP2
SEQ ID No. 19:	sequence of cDNA clone pGL3-22 (incorporated primer regions have not been added)
SEQ ID No. 20:	sequence of cDNA clone pGL4-2 (incorporated primer regions have not been added)
SEQ ID No. 21:	primer glP4
SEQ ID No. 22:	primer glP5
SEQ ID No. 23:	sequence of 5' RACE Anchor (Clontech)
SEQ ID No. 24:	sequence of 5' RACE Anchor primer (Clontech)
SEQ ID No. 25:	sequence of cDNA clone pGL6-14 (incorporated primer regions have not been added)
SEQ ID No. 26:	primer gl31
SEQ ID No. 27:	primer gl32
SEQ ID No. 28:	cDNA sequence of the pGL9 clone 22 (primer regions have been included), and corresponding translated protein
SEQ ID No. 29:	amino acid sequence of the protein produced by pGL9 clone 22

Unless otherwise stated in the Examples, all procedures for making and manipulating recombinant DNA are carried out by the standardized procedures as described in volumes 1 and 2 of Ausubel et al., Current Protocols in Molecular Biology, Current Protocols, USA (1994) and Sambrook et al., Molecular Cloning - A Laboratory Manual, Second Ed., Cold Spring Harbor Laboratory Press, NY (1989). Standard methods and materials for plant molecular biology work are

described in Plant Molecular Biology LABFAX, edited by R.R.D. Croy (1993, Bios Scientific Publishers and Blackwell Scientific publications, series editors B.D. Hames and D. Rickwood).

EXAMPLES

5

Example 1

B. oleraceae S-GT protein identification

10 The S-GT protein of *B. oleraceae* spp. *botrytis* was isolated as described by GrootWassink et al. (1994b, supra) which is incorporated herein by reference. The partial amino acid sequence of the isolated thiohydroximate S-glucosyl-transferase was determined. Since the N-terminus was found to be blocked, the purified protein was first subjected to partial tryptic digestion. The following internal peptide fragments were obtained:

- 15 1) Val-Thr-Ile-Ala-Thr-Thr-Tyr-Thr-Ala-Ser-Ser-Ile-Ser-Thr-Pro-Ser-Val-Ser-Val-Glu-Pro-Ile-Ser-Asp-Gly-His-
Asp-Phe-Ile-Pro (SEQ ID No. 1)
2) Ala-Leu-Gln-Gln-Ser-Asn-Phe-Asn-Phe-Leu-Trp-Val-Ile-Lys (SEQ ID No. 2)
3) Gly-His-Val-Val-Val-Leu-Pro-Tyr-Pro-Val-Gln-Gly-His-Leu-Asn-Pro-Met-Val-Gln-Phe-Ala-Lys (SEQ ID No. 3)
4) Ala-Thr-Leu-Ile-Gly-Pro-Met-Ile-Asp-Ser-Ala-Tyr-Leu-Asp-Lys (SEQ ID No. 4)
20 5) Leu-Pro-Glu-Gly-Phe-Val-Glu-Ala-Thr-Lys (SEQ ID No. 5)
6) Phe-Val-Glu-Glu-Val-Trp-Lys (SEQ ID No. 6)
7) Ala-Met-Ser-Glu-Gly-Ser-Ser-Asp-Arg-Ser-Ile-Asn-Glu-Phe-Val-Glu-Ser-Leu-Gly-Lys (SEQ ID No. 7)

These fragments represent about 1/4 of the *B. oleraceae* S-GT protein sequence and unambiguously characterize
25 the S-GT enzyme.

Searches in protein sequence databases showed that the protein characterized by the above peptide fragments 1 to 7 is unique and has no significant sequence similarity with any previously known protein. Also, each of the peptide fragments 1 to 7 were not found to be included in any known protein. A peptide fragment of a protein showing 85 % sequence similarity with the short fragment 6 was found to be the closest match. Thus, each of the fragments identified
30 above specifically identifies the isolated S-GT protein of *B. oleraceae*.

Example 2

Isolation of a *B. napus* s-gt gene

35

Total RNA was prepared from *B. napus* cv. Westar seedlings that germinated for 5 days in the dark following routine extraction techniques. About 1 mg RNA per gram tissue was obtained as was established by OD₂₆₀ measurements. RNA quality was checked on a 2% TBE agarose gel (under RNase free conditions) for absence of high molecular weight (MW) DNA and integrity. mRNA was prepared from 1 mg of total RNA using the Promega kit "PolyAttract mRNA Isolation System IV" as described by the suppliers. Approximately 2-4 µg of mRNA was recovered.

From the 7 peptide sequences derived from the purified *B. oleraceae* S-GT protein (SEQ ID Nos 1-7), 7 sets of complementary degenerated primers (of which 2 were nested sets) were selected and synthesized by conventional methods. PCR-RACE (rapid amplifying of cDNA ends) with combining degenerate primers (based on the *B. oleraceae* peptide fragments) and the 3' Anchor primer of the 3' RACE kit (Clontech) was used directly. Combinations of these 45 primer sets were tried in PCR reactions on first strand cDNA made with the Clontech kit "3'AmpliFINDER™ RACE Kit" following the instructions of the supplier. This 3'RACE cDNA was used in PCR reactions where primers gI3 (SEQ ID No. 8) or gI7 (SEQ ID No. 9) were combined with the Anchor Primer of the Clontech 3'RACE kit (SEQ ID No. 11; complementary primer to the NN₁ oligo (dT)₁₈ CDS Primer (shown in SEQ ID No. 10)). Both PCR reactions were used as a template for a second semi-nested PCR with anchor primer and respectively primer gI5 (SEQ ID No. 12) or gI9 (SEQ 50 ID No. 13). In the first case (for the gI3-gI5 combination) a PCR fragment of approximately 650bp was amplified. Upon A/T cloning of this fragment in the vector pGEM-T (Promega) following the instructions of the suppliers and electrotransformation in *E.coli* SURE (Stratagene) cells, two of the resulting transformants (pGL2 clones 7 and 25) having the appropriate insert size were sequenced. Analysis of the sequences showed an open reading frame of about 470bp, a 104bp 3'UTR and the polyA⁺tail for both clones. The sequence determined for pGL2-7 is shown in SEQ ID No. 14, that for pGL2-25 in SEQ ID No. 15. The amino acid sequence of the protein fragment encoded by the open reading frame contained in both these clones revealed part of the S-GT peptide 2 (as expected because this sequence was used for PCR-cloning), and the complete S-GT peptides 5, 6 (with one amino acid difference) and 7.

Using the cDNA obtained from the mRNA pool with the 5' RACE kit (Clontech) using the gIP1 primer (SEQ ID No. 17) in a PCR amplification in which the degenerated primers gI1 and gI7 (SEQ ID Nos 16 and 9, respectively) were used

in combination with gIP2 (SEQ ID No. 18) resulted in the generation of specific PCR products of respectively 850bp or 1000bp in length. These two PCR fragments were A/T cloned in the Promega pGEM-T vector as described above and named respectively pGL4-2 and pGL3-22. The PCR product in pGL4 was completely contained in that of pGL3. pGL3 includes 982bp of s-gt ORF, of which the last 116bp overlap the s-gt fragment cloned in pGL2. The sequence of pGL3-22 is shown in SEQ ID No. 19, that of pGL4-2 in SEQ ID No. 20.

5 In addition to the S-GT peptide sequences 2, 5, 6 and 7 previously found in pGL2 the remaining peptide sequences 1, 3 (partially) and 4 (with one amino acid difference) were now located.

In order to clone the remaining 5'end of the *B.napus* s-gt gene 5'RACE was used, with a new set of nested gene 10 specific primers located at the 5' end of the pGL3 PCR insert, namely gIP4 and gIP5 (SEQ ID Nos 21 and 22, respectively). The Clontech 5' AmpliFINDER™ RACE Kit was used according to the supplier's recommendations. The first strand cDNA was generated by reverse transcriptase using primer gIP4, and ligated to the 5' RACE AmpliFINDER™ 15 Anchor (SEQ ID No. 23). Upon amplification of this first strand with the kit's AmpliFINDER™ anchor primer (SEQ ID No. 24) and the gene specific primer gIP5 a 300bp PCR fragment was generated. After A/T cloning (see above) and transformation in *E.coli* WK6 with blue-white screening, several recombinant clones were sequenced. One of them, pGL6 20 clone14 (pGL6-14), had the desired 5' end of the s-gt gene. The sequence showed an 88bp 5'UTR and a partial ORF of 163bp, including the full DNA sequence of S-GT peptide 3 and the start of S-GT peptide 1 (SEQ ID No. 25).

Based on the sequences of the s-gt cDNA fragments retrieved in the previous steps the forward primer gl31 (5'-TTA 20 TTT TTC TTC TTC CTC CTC T-3', SEQ ID No. 26) and reverse primer gl32 (5'-AGC AAC AAC AAC AAA CAC ACA AGA T-3', SEQ ID No. 27) were designed, located respectively in the 5'UTR and the 3'UTR. These two primers 25 were used in PCR reactions on double-stranded (ds) cDNA of *B.napus* cv. Westar (Superscript Lambda System for cDNA Synthesis and -cloning, BRL; cat.no 8256RT). cDNA was amplified using 0.2 µM of these two primers in a reaction buffer consisting of 20 mM Tris-HCl (pH8.4), 50 mM KCl, 2 mM NaCl, 0.2 µM (each)dNTP-mixture and 2.5 Units of Taq-DNA polymerase (purchased at Gibco-BRL). Amplification conditions consisted of a initial 5 minutes denaturing at 94°C, 30 cycles of 45 sec 94°C denaturing, 60°C annealing for 45 sec, and 3 min of elongation at 72°C. As expected, 30 an amplification product of 1.5 kb was obtained. This DNA product was isolated and cloned in the pGEM-Z vector of Promega by A/T-cloning. One clone was retrieved, namely pGL9 clone 22 (further referred to as "the pGL9 clone"). The sequence of this clone revealed an s-gt cDNA comprising the complete open reading frame (SEQ ID No. 28 shows the 35 full sequence obtained; the regions corresponding to the primers gl31 and gl32 are included at the 5' and 3' end, respectively (note that the region corresponding to primer gl31 is partly deleted during cloning)), with a sequence similarity highest to pGL2-25 and pGL4-2. This cDNA comprises an open reading frame encoding a protein with a calculated m.w. of about 51 kD (50,901). The differences between the coding regions of pGL9-22 and the coding regions comprised in the partial cDNA clones obtained above (pGL2, pGL3, pGL4, and pGL6) are illustrated in Figure 2. This Figure confirms the high degree of sequence similarity between the isolated cDNA fragments. Figure 1 shows the approximate locations of the different cDNA fragments in comparison to the pGL9 cDNA clone, and the primers used in their isolation.

The cDNA clone pGL9-22, contained in the pGEM5Zf(+) vector, has been deposited in *E.coli* strain WK6 at the Belgian Coordinated Collections of Microorganisms (BCCM) - Laboratory for Molecular Biology - Plasmid collection (LMBP) on September 7, 1995 under accession number BCCM-LMBP 3344.

Another full length s-gt cDNA clone was obtained using the Clontech Marathon cDNA Amplification Kit. Here 40 mRNA, isolated using the methods and kits mentioned before, was converted to double-stranded cDNA following the provided protocol. In the following amplification reaction on this material, primers gl31 and gl32 were used in combination with several heat stable DNA polymerases, such as Tag DNA polymerase (Gibco,BRL), PwoI DNA polymerase (Boehringer), Vent DNA polymerase (New England Biolabs, Tth,XL DNA polymerase (Perkin Elmer Cetus, a commercial mixture of Tth DNA polymerase with a small amount of Vent DNA polymerase). Reaction mixtures were all made 45 following the purchasers recommendations for optimizing conditions. Cycling parameters after the initial 5'94°C denaturation step were 30 cycles either of 45°94°C,3°68°C or 45°94°C,45°60°C,2°72°C. After a second round of PCR using 1 µl of a tenfold dilution of the previous PCR, both Tag DNA polymerase (conditions as mentioned above) and Tth,XL DNA polymerase (1XTth,XL DNA polymerase buffer supplemented with 1.0 mM Mg(OAc)2) showed the expected 1.5kb amplification product. The Tth,XL DNA polymerase reaction was done using as primers gl31 and gl32 where respectively PstI and XbaI restriction sites were attached at the 5'end and 3' end. Following XbaI-PstI digestion, the PCR 50 amplified DNA fragment was cloned in pUC19. *E.coli* MC1060 transformation gave approximately 10⁸ transformants/µg transforming vector all having the expected insert, which was named pGL18. Partial DNA sequencing of fragments (1 fragment of 200 to 300 basepairs) of the pGL18 clone 1 shows that the pGL18-1 clone is identical to the corresponding parts in the pGL9 clone (see, e.g., Fig. 2).

55 The coding region of the pGL9 cDNA clone was cloned in the PstI-XbaI sites of the polylinker of the pUC19 expression vector using conventional procedures, so that it is under the control of the lac promoter. Expression of this chimeric gene in *E.coli* by IPTG induction showed a band recognized by rabbit polyclonal anti-*B.oleraceae* S-GT antibody, while this band was not present in the untransformed induced strain, upon Western blotting. The recombinantly produced S-GT protein was confirmed to have a glucosyl-S-transferase activity in the radioassay of GrootWassink et al. (1994b,

supra). This assay was based on the incorporation of [¹⁴C]Glc from UDP-Glc into phenylacetothiohydroximate. As starting material, the above *E. coli* strains containing the pGL14 clone were used. The wild type WK6 *E. coli* strain was used as a control, as well as water. Strains were grown and induced (with IPTG) overnight. A Western blot and a Coomassie staining were first performed to check for expression of the formed fusion protein. The protein concentration was assessed by a Bradford assay, using BSA as a standard. For the glucosinolate assay, 80 µl of reaction mixture (50 mM Mes buffer with UDP-[U¹⁴C]Glc (0.05 µCi) and 1.0 mM phenyl acetothiohydroximate, 5 mM MgSO₄ and 0.1% ME) was mixed with 20 µl of extract (from 1 ml of overnight culture that went 3 times through the French press, 800 Pa/inch²; in a 1/100 or 1/500 dilution, depending on the protein concentration of each of the two samples). The samples were incubated at 30°C in a water bath and the reaction was stopped by boiling for 10 min. After cooling on ice, 500 µl ethylacetate was added and the tube containing the samples were vigorously shaken. Samples were spun down and the top phase (containing the glucosinolate in ethylacetate) was recovered for radioactivity measurement.

The results showed that, at the proper dilution of the cell extract (between 1/100 and 1/500 depending on the sample), the enzyme activity increased with time and was significantly higher than the controls. Using the 0 min reaction as a control, the following relative enzyme activities were obtained after different time periods: 22 after 10 minutes (i.e., the glucosyltransferase activity after 10 minutes of incubation with the reaction mixture was 22 times that of the activity of the recombinant s-gt strain at time 0), 30 after 20 min, 40 after 30 min and 80 after 60 min.

Using the wild type *E. coli* strain as a control, the following relative enzyme activities were observed for the S-GT-producing clone: 1 after 0 min reaction, 23 after 10 min (i.e., after 10 minutes of reaction, the S-GT-producing strain had 23 times the glucosyl-transferase activity of the wild type strain), 16 after 20 min, and 65 after 30 min. Thus, these radioassays show that the s-gt gene cloned in the transformed *E. coli* WK6 produced a protein with a significant S-GT activity, thus confirming that the correct DNA sequence had been isolated. The S-GT proteins encoded by the full open reading frames of the other isoforms corresponding to the cDNA fragments isolated above show the same significant S-GT activity under similar assay conditions.

In a next step, the complete *Brassica napus* s-gt gene is cloned from a genomic DNA library using the above sequence information. The promoter region of the s-gt gene is identified in the genomic clone corresponding to the cDNA contained in plasmid pGL9 (as deposited under deposit number BCCM-LMBP 3344). The promoter region, consisting of a DNA sequence comprising 1000 bp upstream of the open reading frame, is isolated for further construction work.

30 Example 3:

Antisense inhibition of s-gt gene expression in oilseed rape plants

Using standard plant molecular biology techniques, several constructs based on the above isolated full cDNA (pGL9, SEQ ID No. 28) are inserted into oilseed rape plant cells which are then regenerated into plants. A *B. napus* variety having more than 30 µmoles of alkenyl glucosinolate per gram oil free seed matter is transformed with the s-gt antisense constructs of Example 3. Hypocotyl explants of *Brassica napus* are obtained, cultured and transformed essentially as described by De Block et al. (1989, Plant Physiol. 91, 694), except for the following modifications:

- 40 - hypocotyl explants are precultured for 3 days in A2 medium [MS, 0.5 g/l Mes (pH 5.7), 1.2% glucose, 0.5% agarose, 1 mg/l 2,4-D, 0.25 mg/l naphthalene acetic acid (NAA) and 1 mg/l 6-benzylaminopurine (BAP)].
- infection medium A3 is MS, 0.5 g/l Mes (pH 5.7), 1.2% glucose, 0.1 mg/l NAA, 0.75 mg/l BAP and 0.01 mg/l gibberellinic acid (GA3).
- selection medium A5 is MS, 0.5 g/l Mes (pH 5.7), 1.2% glucose, 40 mg/l adenine.SO₄, 0.5 g/l polyvinylpolypyrrolidine (PVP), 0.5% agarose, 0.1 mg/l NAA, 0.75 mg/l BAP, 0.01 mg/l GA3, 250 mg/l carbenicillin, 250 mg/l triacillin, 0.5 mg/l AgNO₃.
- regeneration medium A6 is MS, 0.5 g/l Mes (pH 5.7), 2% sucrose, 40 mg/l adenine.SO₄, 0.5 g/l PVP, 0.5% agarose, 0.0025mg/l BAP and 250 mg/l triacillin.
- healthy shoots are transferred to rooting medium which was A8: 100-130 ml half concentrated MS, 1% sucrose (pH 5.0), 1 mg/l isobutyric acid (IBA), 100 mg/l triacillin added to 300 ml perlite (final pH 6.2) in 1 liter vessels (MS stands for Murashige and Skoog medium (Murashige and Skoog, 1962, Physiol. Plant. 15, 473)).

Hypocotyl explants are infected with *Agrobacterium tumefaciens* strain C58C1Rif® carrying:

- 55 - a helper Ti-plasmid pMP90 (Koncz and Schell (1986), Mol. Gen. Genet. 204, 383) or a derivative thereof (such as pGV4000), which is obtained by insertion of a bacterial chloramphenicol resistance gene linked to a 2.5 kb fragment having similarity with the T-DNA vector pGSV8, into pMP90.
- T-DNA vector pGSV8 containing between the T-DNA borders the chimeric s-gt inhibitory gene.

B. napus plants are transformed to contain the following chimeric s-gt inhibitory gene in plant transformation vector pGSV8: a chimeric gene comprising:

- 5 - the 35S3 promoter (Hull and Howell, 1987, *Virology* 86, 482-493) operably linked to one of the following different DNA sequences:

- 10 1) a DNA encoding an antisense RNA complementary to the about 0.7 Kb Styl-Xhol fragment of the s-gt DNA sequence contained in pGL9 (the 5' half of the s-gt coding region), or
 15 2) a DNA encoding an antisense RNA complementary to the about 0.65 Kb Avall-Asnl fragment of the s-gt DNA sequence contained in pGL9 (the 3' half of the s-gt coding region), or
 20 3) a DNA encoding an antisense RNA complementary to the about 1.3 kb Styl-Asnl fragment of the s-gt DNA sequence contained in pGL9 (the almost complete s-gt coding region).

These 3 sequences were each operably linked to the 3' transcript termination and polyadenylation region of the nopaline synthase gene (DePicker et al., 1982, *J. Mol. Appl. Genet.* 1, 561), thus giving 3 chimeric genes, each comprising a DNA encoding a different antisense RNA.

To select the transformed cells, a chimeric bar gene (De Almeida et al., 1989, *Mol. Gen. Genet.* 218, 78) conveying resistance to phosphinotricine is included in the transforming DNA. The bar coding region (Thompson et al., 1987, *The EMBO J.* 6, 2519) is under the control of the promoter of the Arabidopsis thaliana ribulose-1,5-biphosphate carboxylase small subunit 1A gene (Krebbes et al., 1988, *Plant Mol. Biol.* 11, 745) and is flanked by the 3' transcript termination and polyadenylation region of gene 7 (Velten and Schell, 1985, *Nucleic Acids Res.* 13, 6981-6999).

The thus obtained vectors pTKV8, 9 and 10, carry the selectable marker gene in two orientations compared to the s-gt antisense DNA chimeric gene, yielding pTKV8a, pTKV8b, pTKV9a, pTKV9b, pTKV10a, and pTKV10b (a in same orientation, b in opposite orientation of transcription). Plasmid pTKV8a, producing an antisense RNA in plant cells complementary to most of the pGL9 s-gt coding region, was deposited in host cell E. coli MC1061 at the BCCM-LMBP on September 7, 1995 under accession number LMBP 3343.

Following similar procedures, the above (antisense) plant transformation constructs are also made with DNA encoding antisense RNA complementary to the RNA corresponding to all or part of the open reading frame corresponding to the pGL6 clone described above. In other transformation steps, Brassica juncea varieties are also transformed with the pGL9-derived antisense constructs pTKV8, pTKV9 and pTKV10, so as to obtain plants with markedly decreased glucosinolate content in their seeds.

Example 4:

35 **Plant selection and agronomic evaluation**

The transformed oilseed lines of Example 3, having a single copy antisense s-gt chimeric gene and having reduced glucosinolate content in the seeds, are selected upon transformation. These selected transformed plants are rendered homozygous by doubled haploid methodology, and the obtained homozygous lines are then crossed with a male sterile *B. napus* variety (obtained by following the teachings of EP 344029 and Mariani et al. (1990, *Nature* 347, 737-741; 1992, *Nature* 357, 384-387)) to obtain a hybrid having reduced glucosinolate content and being male sterile. The decrease of glucosinolate content in hybrids obtained from crosses of different *B. napus* varieties with known glucosinolate levels with the obtained selected male sterile hybrid plants allows the quantitative determination of the reduction in glucosinolate content in a hemizygous state in a hybrid plant. A statistically significant reduction (see, for example, Statistical Methods, eds. Snedecor, G.W. and Cochran, Wig, Iowa State, University Press Iowa, USA, 1976) in alkenyl glucosinolate levels is found in the seeds of selected hybrid plants, thus illustrating that the glucosinolate content in Brassica varieties still having high glucosinolate levels in their seeds can be lowered to agronomically acceptable levels.

Agronomic evaluation of the obtained transformed plants and the resulting hybrids shows that these plants have good yields when compared to hybrids obtained from crossing plants not transformed with the s-gt antisense chimeric gene.

Additional plants wherein the invention is applicable are all other plants wherein a reduced expression of an UDP-glucose:thiohydroximate S-glucosyltransferase is desired, or wherein reduction of glucosinolate content is desired in view of the negative effects of the glucosinolates on animal or human consumption. Exemplary crops wherein the above embodiments are as well applicable are other oilseed rape species and other Crucifer crops, particularly other Brassica crops, including but not limited to: B. oleracea, B. campestris, B. rapa, B. juncea, and B. nigra. Because of the large sequence similarity between the different S-GT isoforms and their encoding genes, it is believed that the constructs of Example 3 can equally well be used to obtain a reduced glucosinolate content in these other Brassica plants, preferably in their seeds.

The examples and embodiments of this invention described herein are only supplied for illustrative purposes. Many

variations and modifications in accordance with the present invention are known to the person skilled in the art and are included in this invention and the scope of the claims. For instance, it is possible to alter, delete or add some nucleotides or amino acids to the DNA and protein sequences of the invention without departing from the essence of the invention.

All publications (including patent publications) referred to in this application are hereby incorporated by reference.

5

SEQUENCE LISTING

(1) GENERAL INFORMATION:

10

- (i) APPLICANT:
(A) NAME: PLANT GENETIC SYSTEMS N.V.
(B) STREET: Plateaustraat 22
(C) CITY: Gent
(E) COUNTRY: BELGIUM
(F) POSTAL CODE (ZIP): B-9000
(G) TELEPHONE: 32 9 2358454
(H) TELEFAX: 32 9 2240694

(A) NAME: NATIONAL RESEARCH COUNCIL OF CANADA
(B) STREET: Montreal Road
(C) CITY: Ottawa
(D) STATE: Ontario
(E) COUNTRY: CANADA
(F) POSTAL CODE (ZIP): K1A 0R6
(G) TELEPHONE: 1 613 9933899
(H) TELEFAX: 1 613 9526082
- (ii) TITLE OF INVENTION: Plants with reduced glucosinolate content
- (iii) NUMBER OF SEQUENCES: 29
- (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

15

20

25

(2) INFORMATION FOR SEQ ID NO: 1:

30

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

40

Val Thr Ile Ala Thr Thr Thr Tyr Thr Ala Ser Ser Ile Ser Thr Pro
1 5 10 15
Ser Val Ser Val Glu Pro Ile Ser Asp Gly His Asp Phe Ile Pro
20 25 30

45

(2) INFORMATION FOR SEQ ID NO: 2:

50

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Ala Leu Gln Gln Ser Asn Phe Asn Phe Leu Trp Val Ile Lys
1 5 10

5

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

10

- (ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Gly His Val Val Val Leu Pro Tyr Pro Val Gln Gly His Leu Asn Pro
1 5 10 15

20

Met Val Gln Phe Ala Lys
20

25

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

25

- (ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Ala Thr Leu Ile Gly Pro Met Ile Asp Ser Ala Tyr Leu Asp Lys
1 5 10 15

35

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

40

- (ii) MOLECULE TYPE: peptide

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

45

Leu Pro Glu Gly Phe Val Glu Ala Thr Lys
1 5 10

50

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Phe Val Glu Glu Val Trp Lys
1 5

10

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Ala Met Ser Glu Gly Gly Ser Ser Asp Arg Ser Ile Asn Glu Phe Val
1 5 10 15
Glu Ser Leu Gly Lys
20

25

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

35

CARGARWSNA AYTYYAAYTT

20

(2) INFORMATION FOR SEQ ID NO: 9:

40

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CCNTAYCCNG TNCARGGNCA

20

(2) INFORMATION FOR SEQ ID NO: 10:

50

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

CCTCTGAAGG TTCCAGAAC GATAGGAATT CTTTTTTTTT TTTTTTTTV N

5 51

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
10 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

15 CTGGTTCGGC CCACCTCTGA AGGTTCCAGA ATCGATAG

38

(2) INFORMATION FOR SEQ ID NO: 12:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
20 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

AAYTTYYTNT GGGTNATHAA

20

(2) INFORMATION FOR SEQ ID NO: 13:

- (i) SEQUENCE CHARACTERISTICS:
30 (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CCNATGGTNC ARTTYGCNAA

20

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
40 (A) LENGTH: 566 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- 45 (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

AGAAGCTCAT ATAGCGAAGT TACCAAGG GTTTGTGGAA GCTACCAAAG ACAGAGCGTT

60

EP 0 771 878 A1

	GCTTGTTCCT TGGTGTAACC AGCTTGAGGT TTTAGCTCAT GGATCTATAG GTTGTTCCT	120
	GACTCACTGC GGTTGGAACCT CGACGCTGGA AGGGTTGAGT TTGGGAGTTC CGATGGTGGG	180
5	TGTGCCCGCAG TGGAGTGATC AGATGAATGA TGCTAAGTTT GTGGAGGAGG TTTGGAGAGT	240
	TGGGTATAGA GCGAAAGATG AAGCTGGGGG AGGAGTTGTG AAGAGCGATG AGGTGGTGAG	300
	GTGTTGAAA GGAGTGATGG AAGGAGAGAG TAGTGTGGAG ATTAGAGAAA GTTCTAAGAA	360
10	ATGGAAAGAT TTGGCTGTGA AGGCGATGAG TGAAGGAGGA AGCTCTGATC GGAGCATTAA	420
	TGAGTTGTTG GAGAGTTTAG GGAAGAACACA TTGAGAGGTA ATGAGATTG TAAATCTTGT	480
	GTGTTGTTG TTGTTGCTCA AGAGCATTGT ACGGAGCGGA TTGTCATTCA GTAATATGAA	540
	TAAACCAATT GTGATAGTAA AAAAAAA	566

15 (2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 568 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

	AGAAGCTCAT ATAGCGAAGT TACCAAGAGG GTTGTGGAA GCTACCAAAG ACAGAGCGTT	60
	GCTTGTTCCT TGGTGTAACC AGCTTGAGGT TTTAGCTCAT GAATCGATAAG GTTGTTCCT	120
30	GACTCACTGC GGTTGGAACCT CGACGTTGGA AGGATTGAGT TTGGGAGTTC CGATGGTGG	180
	TGTGCCCTCAG TGGAGTGATC AGATGAATGA TGCTAAGTTT GTGGAGGAGG TTTGGAGAGT	240
	TGGGTATAGA GCGAAGGAGG AAGCTGGGGG AGGAGTTGTG AAGAGCGATG AGGTGGTGAG	300
35	GTGTTGAGA GGAGTGATGG AAGGAGAGAG TAGTGTGGAG ATTAGAGAGA GTTCTAAGAA	360
	GTGGAAAGAT TTGGCTGTGA AGGCGATGAG TGAAGGAGGA AGCTCTGATC GGAGCATTAA	420
	TGAGTTGTTG GAGAGTCTAG GGAAGAACACA TTGAGAGGTA ATGAGATTG TAAATCTTGT	480
40	GTGTTGTTG TTGTTGCTCA AGAGCATTGT ACGGAGCGGA TTGTCATTCA GTAATATGAG	540
	TAAACCAATT GTGATATTG AAAAAAAA	568

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GAYGGNCAYG AYTTYATHCC

20

(2) INFORMATION FOR SEQ ID NO: 17:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CCTTCCAGCG TCGAGTTCCA ACCGC

25

(2) INFORMATION FOR SEQ ID NO: 18:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

CGGAATTCGC TAAAACCTCA AGCTGGTTAC ACC

33

25 (2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 940 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CACCTCAACC CAATGGTCCA GTTCGCTAAA CGCCTAGTCT CCAAAGGCCT CAAAGTCACA	60
ATGCCACCA CCACCTACAC CGCCTCCTCC ATCTCCACCC CCTCCGTCTC CGTCGAACCA	120
ATCTCCGACG GCCACGACTT CATCCCCATA GGCCTCCCCG GCGTCAGCAT CGACGCCTAC	180
TCCGAATCCT TCAAGCTCCA CGGCTCCCAA ACCTTAACCC GCGTAATCTC CAAATTCAA	240
TCCACAGATT CCCCCATCGA TTCTTTAGTC TACGACTCTT TCCCTCCGTG GGGACTCGAA	300
GTCGGGAGAT CCAACTCCCT CTCAGCTGCC GCTTTCTCA CCAACAACCT CACCGTTTGC	360
TCTGTCCCTTC GCAAATTGCG CTCCGGTGAG TTTCCCTCTCC CCGCTGATCC CGCTTCCGCG	420
CTGTATCTCG TCCGTGGCTT GCCGGCTTGT AGCTACGACG AGCTTCTTC CTTCGTGGGC	480
CGTCACTCGT CGAGCCACGC CGAACACGGG AGAGTTCTTC TGAACCAGTT CATTAACCAT	540
GAAGATGCTG ATTGGCTGTT CGTCAACGGC TTCAAGGGT TAGAGACACA AGGTTGTGAA	600
GTGGAGAAT CAGAGACTAT GAAGGCGACG TTGATCGGAC CTATGATCCC ATCTGCTTAT	660

EP 0 771 878 A1

5 CTTGACGCC CGATAAAGGC TACGGCTCGA GTCTGATGAA GCCGCTCTCG 720
GAGGAGTGTA TGGAGTGGTT AGACACTAAG CTGAGTAAGT CGGTGGTTTT TGTTTCGTTT 780
GGTTCCCTTA GGATCCTCTT TGAGAACCAA CTAGCTGAGG TAGCAACGGC GTTACAAGAA 840
TCCAACCTTA ACTTCTTGTG GGTGATTAAA GAAGCTCGTA TAGCGAAGTT ACCAGAAGGG 900
TTTGTTGGAAG CTACCAAAGA CAGAGCGTTG CTTGTTCTT 940

10 (2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 794 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
- 15 (ii) MOLECULE TYPE: cDNA to mRNA
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

25 CATAGGCGTT CCCGGCGTCA GCATCGACGC ATACTCCGGA TCCTTCAAGC TCAACGGCTC 60
CGAAACCTTA ACCCGAGTAA TCTCAAATT CAAATCCACA GATTCAACCA TCGATTCAATT 120
AGTCTACGAC TCTTTCCCTCC CGTGGGGACT CGAAGTCGCG AGATCTAACT CCATCTCAGC 180
TGCTGCTTTC TTCACCAACA ACCTCACCGT TTGCTCTGTT CTACGCAAAT TCGTCTCCGG 240
TGAGTTTCCT CTCCCCGCTG ATCCCGCTTC CGCGCCGTAT CTGTCCTGTC GCTTACCGGC 300
30 TTTGAGCTAC GACGAGCTTC CTTCCCTCGT CGGACGTCAC TCGTCGAGCC ACGCGGAGCA 360
CGGGAGAGTT CTTCTGAACC AGTTCCGTAA CCACGAAGAT GCTGATTGGC TGTTCGTCAA 420
CGGCTTCGAA GGGTTAGAGA CACAAGGTTG TGAAGTTGGA GAATCAGAGG CGATGAAGGC 480
GACGTTGATC GGACCTATGA TACCATCTGC TTATCTCGAC GGCGAATCA AAGACGATAA 540
35 AGGCTACGGC TCGAGCCTGA TGAAGCCGCT CTCGGAGGAG TGTATGGAGT GGTTAGACAC 600
TAAGCTGAGC AAGTCGGTGG TTTTTGTTTC GTTTGGTTCC TTTGGGATCC TCTTTGAGAA 660
GCAACTCGCT GAGGTGGCAA AGGCCTTACA AGAATCCAAC TTTAACTTCT TGTGGGTGAT 720
40 CAAAGAAGCT CATATAGCGA AGTTACCAAGA AGGGTTTGTG GAAGCTACCA AAGACAGAGC 780
GTTGCTTGTT TCTT 794

(2) INFORMATION FOR SEQ ID NO: 21:

- 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

AGACGGAGGG GGTGGAGATG GAGGAG

26

(2) INFORMATION FOR SEQ ID NO: 22:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

CGGAATTCTGG TGTAGGTGGT GGTGGCGATT GTGAC

35

(2) INFORMATION FOR SEQ ID NO: 23:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

CACGAATTCA CTATCGATTC TGGAACCTTC AGAGG

35

25 (2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 38 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

CTGGTTCCGGC CCACCTCTGA AGGTTCCAGA ATCGATAG

38

35 (2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 223 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

GATCAGACTT ATTATTTTTC TTCTTCCCTCC TCCTCTTCTC AGTCTTCTTC AACTGAAAAC

60

AAACAGAAAC TAAGGCTTCA AAGTCACAAT GGTGGAAACA ACAACAAACAA CAACAGCAA

120

GACCAGCTCC AAAGGCCACG TCTTGGTCTT ACCTTACCCA GTCCAAGGCC ACCTCAACCC

180

AATGGTCCAG TTGCTAAAC GCCTAGTCTC CAAAGGCCTC AAA

223

(2) INFORMATION FOR SEQ ID NO: 26:

5

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

TTATTTTCT TCTTCCTCCT CCTCT

25

15

(2) INFORMATION FOR SEQ ID NO: 27:

20

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

25 AGCAACAACA ACAAACACAC AAGAT 25

(2) INFORMATION FOR SEQ ID NO: 28:

30

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1513 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

35

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 69..1466

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

40 TTATTTTCT TCTTCCTCCT CCTCTGTGTC TTTGTCAACT GCAAACAAAA CAGAAACCAA 60

GTTCTGCA ATG GCG GAA ACA ACA ACA ACA ACA GCG ACC AAC TCC AAA
 Met Ala Glu Thr Thr Thr Thr Thr Ala Thr Asn Ser Lys
 1 5 10

45 GGC CAC GTC GTG GTC TTA CCT TAC CCA GTC CAA GGC CAC CTC AAC CCA 158
 Gly His Val Val Val Leu Pro Tyr Pro Val Gln Gly His Leu Asn Pro
 20 25 30

ATG GTC CAG TTC GCT AAA CGC CTA GTC TCC AAA GGC GTC AAA GTC ACA 206
 Met Val Gln Phe Ala Lys Arg Leu Val Ser Lys Gly Val Lys Val Thr
 35 40 45

50 ATC GCC ACC ACC ACC TAC ACC GCC TCC TCC ATC TCC ACT CCC TCC GTC 254
 Ile Ala Thr Thr Tyr Thr Ala Ser Ser Ile Ser Thr Pro Ser Val
 50 55 60

55

EP 0 771 878 A1

	TCC GTC GAA CCA ATC TCC GAC GGC CAC GAC TTC ATC CTC ATA GGC GTC Ser Val Glu Pro Ile Ser Asp Gly His Asp Phe Ile Leu Ile Gly Val 65 70 75	302
5	CCC GGC GTC AGC ATC GAC GCA TAC TCC GAA TCC TTC AAG CTC AAC GGC Pro Gly Val Ser Ile Asp Ala Tyr Ser Glu Ser Phe Lys Leu Asn Gly 80 85 90	350
	TCC GAA ACC TTA ACC CGA GTA ATC TCA AAA TTC AAA TCC ACA GAT TCA Ser Glu Thr Leu Thr Arg Val Ile Ser Lys Phe Lys Ser Thr Asp Ser 95 100 105 110	398
10	CCC ATC GAT TCA TTA GTC TAC GAC TCT TTC CTC CCG TGG GGA CTC GAA Pro Ile Asp Ser Leu Val Tyr Asp Ser Phe Leu Pro Trp Gly Leu Glu 115 120 125	446
15	GTC GCG AGA TCT AAC TCC ATC TCA GCT GCT GCT TTC ACC AAC AAC Val Ala Arg Ser Asn Ser Ile Ser Ala Ala Ala Phe Thr Asn Asn 130 135 140	494
	CTC ACC GTT TGC TCT GTT CTA CGC AAA TTC GTC TCC GGT GAG TTT CCT Leu Thr Val Cys Ser Val Leu Arg Lys Phe Val Ser Gly Glu Phe Pro 145 150 155	542
20	CTC CCC GCT GAT CCC GCT TCC GCG CCG TAT CTC GTC CGT GGC TTA CCG Leu Pro Ala Asp Pro Ala Ser Ala Pro Tyr Leu Val Arg Gly Leu Pro 160 165 170	590
	GCT TTG AGC TAC GAC GAG CTT CCT TCC TTC GTC GGA CGT CAC TCG TCG Ala Leu Ser Tyr Asp Glu Leu Pro Ser Phe Val Gly Arg His Ser Ser 175 180 185 190	638
25	AGC CAC GCG GAA CAC GGG AGA GTT CTT CTG AAC CAG TTC CGT AAC CAC Ser His Ala Glu His Gly Arg Val Leu Leu Asn Gln Phe Arg Asn His 195 200 205	686
30	GAA GAT GCT GAT TGG CTG TTC GTC AAC AGC TTC GAA GGG TTA GAG ACA Glu Asp Ala Asp Trp Leu Phe Val Asn Ser Phe Glu Gly Leu Glu Thr 210 215 220	734
	CAA GGT TGT GAA GTT GGA GAA TCA GAG GCG ATG AGG GCG ACG TTG ATC Gln Gly Cys Glu Val Gly Glu Ser Glu Ala Met Arg Ala Thr Leu Ile 225 230 235	782
35	GGA CCT ATG ATA CCA TCT GCT TAT CTC GAC GGC CGA ATC AAA GAC GAT Gly Pro Met Ile Pro Ser Ala Tyr Leu Asp Gly Arg Ile Lys Asp Asp 240 245 250	830
	AAA GGC TAC GGC TCG AGC CTG ATG AAG CCG CTC TCG GAG GAG TGT ATG Lys Gly Tyr Gly Ser Ser Leu Met Lys Pro Leu Ser Glu Glu Cys Met 255 260 265 270	878
40	GAG TGG TTA GAC ACT AAG CTG AGC AAG TCG GTG GTT TTT GTT TCG TTT Glu Trp Leu Asp Thr Lys Leu Ser Lys Ser Val Val Phe Val Ser Phe 275 280 285	926
	GGT TCC TTT GGG ATC CTC TTT GAG AAG CAA CTC GCT GAG GTG GCA AAG Gly Ser Phe Gly Ile Leu Phe Glu Lys Gln Leu Ala Glu Val Ala Lys 290 295 300	974
45	GCG TTA CAA GAA TCC AAC TTT AAC TTC TTG TGG GTG ATC AAA GAA GCT Ala Leu Gln Glu Ser Asn Phe Asn Phe Leu Trp Val Ile Lys Glu Ala 305 310 315	1022
	CAT ATA GCG AAG TTA CCA GAA GGG TTT GTG GAA GCT ACC AAA GAC AGA His Ile Ala Lys Leu Pro Glu Gly Phe Val Glu Ala Thr Lys Asp Arg 320 325 330	1070

EP 0 771 878 A1

	GCG TTG CTT GTT TCT TGG TGT AAC CAG CTT GAG GTT TTA GCT CAT GTA Ala Leu Leu Val Ser Trp Cys Asn Gln Leu Glu Val Leu Ala His Val 335 340 345 350	1118
5	TCG ATA GGT TGC TTT TTG ACT CAC TGC GGT TGG AAC TCG ACG TTG GAA Ser Ile Gly Cys Phe Leu Thr His Cys Gly Trp Asn Ser Thr Leu Glu 355 360 365	1166
10	GGA TTG AGT TTG GGA GTT CCG ATG GTT GGT GTG CCT CAG TGG AGT GAT Gly Leu Ser Leu Gly Val Pro Met Val Gly Val Pro Gln Trp Ser Asp 370 375 380	1214
	CAG ATG AAT GAT GCT AAG TTT GTG GAG GAG GTT TGG AGA GTT GGG TAT Gln Met Asn Asp Ala Lys Phe Val Glu Glu Val Trp Arg Val Gly Tyr 385 390 395	1262
15	AGA GCG AAG GAG GAA GCT GGG GGA GGA GTT GTG AAG AGC GAT GAG GTG Arg Ala Lys Glu Glu Ala Gly Gly Val Val Lys Ser Asp Glu Val 400 405 410	1310
	GTG AGG TGT TTG AGA GGA GTG ATG GAA GGA GAG AGT AGT GTG GAG ATT Val Arg Cys Leu Arg Gly Val Met Glu Gly Glu Ser Ser Val Glu Ile 415 420 425 430	1358
20	AGA GAG AGT TCT AAG AAG TGG AAA GAT TTG GCT GTG AAG GCG ATG AGT Arg Glu Ser Ser Lys Lys Trp Lys Asp Leu Ala Val Lys Ala Met Ser 435 440 445	1406
	GAA GGA GGA AGC TCT GAT CGG AGC ATT AAT GAG TTT GTG GAG AGT CTA Glu Gly Gly Ser Ser Asp Arg Ser Ile Asn Glu Phe Val Glu Ser Leu 450 455 460	1454
25	GGG AAG AAA CAT TGAGAGGTAA TGAGATTTGT AAATCTTGTG TGTTTGTTGT Gly Lys Lys His 465	1506
	TGTTGCT	1513
30	(2) INFORMATION FOR SEQ ID NO: 29:	
	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 466 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear	
35	(ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:	
	Met Ala Glu Thr Thr Thr Thr Ala Thr Asn Ser Lys Gly His 1 5 10 15	
40	Val Val Val Leu Pro Tyr Pro Val Gln Gly His Leu Asn Pro Met Val 20 25 30	
	Gln Phe Ala Lys Arg Leu Val Ser Lys Gly Val Lys Val Thr Ile Ala 35 40 45	
45	Thr Thr Thr Tyr Thr Ala Ser Ser Ile Ser Thr Pro Ser Val Ser Val 50 55 60	
	Glu Pro Ile Ser Asp Gly His Asp Phe Ile Leu Ile Gly Val Pro Gly 65 70 75 80	
50	Val Ser Ile Asp Ala Tyr Ser Glu Ser Phe Lys Leu Asn Gly Ser Glu 85 90 95	
	Thr Leu Thr Arg Val Ile Ser Lys Phe Lys Ser Thr Asp Ser Pro Ile 100 105 110	

EP 0 771 878 A1

Asp Ser Leu Val Tyr Asp Ser Phe Leu Pro Trp Gly Leu Glu Val Ala
 115 120 125
 5 Arg Ser Asn Ser Ile Ser Ala Ala Ala Phe Phe Thr Asn Asn Leu Thr
 130 135 140
 Val Cys Ser Val Leu Arg Lys Phe Val Ser Gly Glu Phe Pro Leu Pro
 145 150 155 160
 10 Ala Asp Pro Ala Ser Ala Pro Tyr Leu Val Arg Gly Leu Pro Ala Leu
 165 170 175
 Ser Tyr Asp Glu Leu Pro Ser Phe Val Gly Arg His Ser Ser Ser His
 180 185 190
 Ala Glu His Gly Arg Val Leu Leu Asn Gln Phe Arg Asn His Glu Asp
 195 200 205
 15 Ala Asp Trp Leu Phe Val Asn Ser Phe Glu Gly Leu Glu Thr Gln Gly
 210 215 220
 Cys Glu Val Gly Glu Ser Glu Ala Met Arg Ala Thr Leu Ile Gly Pro
 225 230 235 240
 20 Met Ile Pro Ser Ala Tyr Leu Asp Gly Arg Ile Lys Asp Asp Lys Gly
 245 250 255
 Tyr Gly Ser Ser Leu Met Lys Pro Leu Ser Glu Glu Cys Met Glu Trp
 260 265 270
 25 Leu Asp Thr Lys Leu Ser Lys Ser Val Val Phe Val Ser Phe Gly Ser
 275 280 285
 Phe Gly Ile Leu Phe Glu Lys Gln Leu Ala Glu Val Ala Lys Ala Leu
 290 295 300
 30 Gln Glu Ser Asn Phe Asn Phe Leu Trp Val Ile Lys Glu Ala His Ile
 305 310 315 320
 Ala Lys Leu Pro Glu Gly Phe Val Glu Ala Thr Lys Asp Arg Ala Leu
 325 330 335
 35 Leu Val Ser Trp Cys Asn Gln Leu Glu Val Leu Ala His Val Ser Ile
 340 345 350
 Gly Cys Phe Leu Thr His Cys Gly Trp Asn Ser Thr Leu Glu Gly Leu
 355 360 365
 Ser Leu Gly Val Pro Met Val Gly Val Pro Gln Trp Ser Asp Gln Met
 370 375 380
 40 Asn Asp Ala Lys Phe Val Glu Val Trp Arg Val Gly Tyr Arg Ala
 385 390 395 400
 Lys Glu Glu Ala Gly Gly Val Val Lys Ser Asp Glu Val Val Arg
 405 410 415
 45 Cys Leu Arg Gly Val Met Glu Gly Glu Ser Ser Val Glu Ile Arg Glu
 420 425 430
 Ser Ser Lys Lys Trp Lys Asp Leu Ala Val Lys Ala Met Ser Glu Gly
 435 440 445
 50 Gly Ser Ser Asp Arg Ser Ile Asn Glu Phe Val Glu Ser Leu Gly Lys
 450 455 460
 Lys His
 465

Claims

1. A plant, transformed to contain a chimeric gene comprising:

- 5 (a) a plant-expressible promoter,
- (b) a transcribed region operably linked to said promoter, comprising a DNA sequence encoding an RNA or protein, wherein said RNA or protein interfere with the normal expression of the UDP-glucose:thiohydroximate S-glucosyltransferase gene (s-gt gene) in cells of said plant, and
- (c) a 3' transcription termination and polyadenylation region active in said plant.

10 2. The plant of claim 1, wherein said transcribed region comprises a DNA sequence selected from the following:

- 15 1) a DNA encoding an antisense RNA which is at least 80 % complementary, preferably at least 90 % complementary to the sense RNA encoded by an s-gt gene in a plant, or which has at least 80 %, preferably at least 90 %, sequence similarity to parts of said sense RNA of at least 100 nucleotides, preferably of at least 500 nucleotides;
- 20 2) a DNA encoding an antisense RNA which is at least 80 % complementary, preferably at least 90 % complementary, to at least 100 nucleotides, preferably at least 500 nucleotides, of the RNA encoded by the s-gt gene, the cDNA of which is comprised in plasmid pGL9, deposited in E. coli WK6 at the BCCM-LMBP under deposit number 3344;
- 25 3) a DNA encoding an antisense RNA which is at least 80 % complementary, preferably at least 90 % complementary, to at least 100 nucleotides, preferably at least 500 nucleotides, of the RNA encoded by the s-gt gene, the cDNA of which has the sequence of SEQ ID No. 28, or a DNA having substantial sequence similarity thereto.

30 3. The plant of claim 1, wherein said transcribed region comprises a DNA sequence encoding a sense RNA which has at least 80 % sequence similarity, preferably at least 90 % sequence similarity, more preferably at least 95 % sequence similarity, to a region of at least 100 nucleotides, preferably a region of at least 500 nucleotides, of the following RNAs:

- 35 1) an RNA encoded by the s-gt gene, the cDNA of which is comprised in plasmid pGL9, deposited in E. coli WK6 at the BCCM-LMBP under deposit number 3344, or
- 2) an mRNA, the cDNA of which is shown in SEQ ID No. 28.

40 4. The plant of claim 1, wherein said transcribed region comprises a DNA sequence encoding a ribozyme with a targeting region which is at least 90%, preferably at least 95 %, complementary to part of the following RNAs:

- 45 1) an RNA encoded by the s-gt gene characterized by the cDNA comprised in plasmid pGL9, deposited in E. coli WK6 at the BCCM-LMBP under deposit number 3344, or
- 2) an mRNA, the cDNA of which is shown in SEQ ID No. 28.

50 5. The plant of any one of claims 1 to 4, wherein said plant-expressible promoter is chosen from amongst the following group: a constitutive plant-expressible promoter, a 35S promoter, the promoter of the s-gt gene encoding an mRNA, the cDNA of which is comprised in E. coli WK6 deposited at the BCCM-LMBP under deposit number 3344, the promoter of the gene encoding an RNA, the cDNA of which has the sequence of SEQ ID No. 28, a pod tissue-specific promoter, a pod wall-specific promoter.

55 6. A DNA comprising a region encoding a protein with UDP-glucose:thiohydroximate S-glucosyltransferase activity, selected from the following:

- 60 1) a DNA encoding an mRNA, the cDNA of which is contained in plasmid pGL9, deposited in E. coli WK6 at the BCCM-LMBP under accession number 3344;
- 2) a DNA encoding an mRNA, the cDNA of which has the sequence of SEQ ID No. 28;
- 3) a DNA having substantial sequence homology to the DNA of SEQ ID No. 28.

55 7. A DNA sequence encoding an antisense RNA selected from the following:

- 65 1) an antisense RNA which is complementary, preferably at least 90 % complementary, more preferably at least 95 % complementary, to a region of at least 100 nucleotides, preferably a region of at least 500 nucle-

otides, of an mRNA, the cDNA of which is contained in plasmid pGL9, deposited in *E. coli* WK6 at the BCCM-LMBP under accession number 3344;

5 2) an antisense RNA, which is at least 90 % complementary, more preferably at least 95 % complementary, to a region of at least 100 nucleotides, preferably a region of at least 500 nucleotides, of an mRNA, the cDNA of which comprises the coding region of SEQ ID No. 28; or

10 3) an antisense RNA encoded by the *s-gt* inhibitory gene contained in plasmid pTKV8a included in *E. coli*, MC1061, deposited at the BCCM-LMBP under accession number LMBP 3343, or an RNA having substantial sequence homology thereto.

15 10. 8. A purified plant protein, characterized by having UDP-glucose:thiohydroximate S-glucosyltransferase activity and comprising:

1) any of the peptide fragments of SEQ ID No. 1 to 7; or

15 2) a region having at least 90 % sequence similarity, preferably at least 95 % sequence similarity, to any of the peptide fragments of SEQ ID Nos 1, 2, 3, 4, or 7.

9. The protein encoded by the cDNA contained in plasmid pGL9, deposited in *E. coli* WK6 at the BCCM-LMBP under accession number 3344, particularly the protein with the sequence of SEQ ID No. 28.

20 10. A DNA sequence encoding the protein of claims 8 or 9.

11. A plant, particularly a *Brassica* plant, more particularly a *Brassica napus* plant, transformed with any of the chimeric genes of claims 1 to 4, so to contain a level of total glucosinolates, preferably alkenyl glucosinolates, which is lower than 30 μ moles per gram dry defatted seed.

25 12. A *Brassica napus* plant, transformed so as to contain less than 30 μ moles, preferably less than 15 μ moles, particularly less than 5 μ moles, of alkenyl glucosinolates per gram of dry defatted seed.

30 13. A process for obtaining a *Brassica napus* plant having a significantly reduced expression of an *s-gt* gene, comprising the following steps:

- a) transforming a plant cell with any of the chimeric genes of claims 1 to 4;
- b) regenerating a plant from said transformed cell.

35 14. A process for obtaining a *Brassica napus* plant having a significantly reduced content of glucosinolates in its seeds, comprising the following steps:

- a) transforming a plant cell with any of the chimeric genes of claims 1 to 4;
- b) regenerating a plant from said transformed cell.

40 15. A seed, obtained from the plant of any of claims 1-4, and claims 11 or 12, comprising the chimeric gene of any of claims 1 to 4.

16. A seed cake, obtained by crushing the seed of claim 15.

45 17. The chimeric gene of any of claims 1 to 4.

18. A hybrid *Brassica* plant containing less than 30 μ moles of alkenyl glucosinolates per gram of dry defatted seed matter, obtained from two parent plants, at least one of which has total glucosinolate levels of more than 30 μ moles, preferably more than 50 μ moles, per gram dry defatted seed.

50 19. A hybrid *Brassica* plant containing less than 5 μ moles per gram of total glucosinolate levels in the whole seed basis, obtained from two parent plants, at least one of which has total glucosinolate levels of more than 5 μ moles, preferably more than 50 μ moles, per gram in the defatted seed meal.

55 20. A hybrid *Brassica* plant containing no detectable glucosinolates in the seeds, obtained from two parent plants, at least one of which has glucosinolate levels above 0 μ moles, preferably above 50 μ moles in the defatted seed meal.

Figure 1. Schematic representation of S-GT cDNA clones




Figure 2: variants of the pGL9 clone

<6

insert AAG at | (6)

T(6)	A(6) G(6)	
<u>ATG GcG GAA ACA ACA ACA ACA ACA GCg</u>	<u> ACC Aac TCC AAA GGC CAC</u>	
Met Ala Glu Thr Thr Thr Thr Ala Thr Asn Ser Lys Gly His		
1	5	10
		15

<3

<u>GTC GTG GTC TTA CCT TAC CCA GTC CAA GGC CAC CTC AAC CCA ATG GTC</u>		
Val Val Val Leu Pro Tyr Pro Val Gln Gly His Leu Asn Pro Met Val		
20	25	30
		6>
	C(3)	
	C(6)	
<u>CAG TTC GCT AAA CGC CTA GTC TCC AAA GGC gTC AAA GTC ACA ATC GCC</u>		
Gln Phe Ala Lys Arg Leu Val Ser Lys Gly Val Lys Val Thr Ile Ala		
35	40	45

C(3)

<u>ACC ACC ACC TAC ACC GCC TCC TCC ATC TCC ACT CCC TCC GTC TCC GTC</u>		
Thr Thr Thr Tyr Thr Ala Ser Ser Ile Ser Thr Pro Ser Val Ser Val		
50	55	60

C(3)

<4

<u>GAA CCA ATC TCC GAC GGC CAC GAC TTC ATC CtC ATA GGC GTc CCC GGC</u>		
Glu Pro Ile Ser Asp Gly His Asp Phe Ile Leu Ile Gly Val Pro Gly		
65	70	75
		80

C(3) G(4)

C(3) C(3)

<u>GTC AGC ATC GAC GCa TAC TCC GaA TCC TTC AAG CTC aAC GGC TCC gAA</u>		
Val Ser Ile Asp Ala Tyr Ser Glu Ser Phe Lys Leu Asn Gly Ser Glu		
85	90	95

C(3) C(3)

C(3)

<u>ACC TTA ACC CGa GTA ATC TCa AAA TTC AAA TCC ACA GAT TCa CCC ATC</u>		
Thr Leu Thr Arg Val Ile Ser Lys Phe Lys Ser Thr Asp Ser Pro Ile		
100	105	110

EP 0 771 878 A1

T(3)

GAT TC_a TTA GTC TAC GAC TCT TTC CTC CCG TGG GGA CTC GAA GTC GCG
Asp Ser Leu Val Tyr Asp Ser Phe Leu Pro Trp Gly Leu Glu Val Ala
115 120 125

C(3)

C(3)

C(3)

AGA TC_t AAC TCC aTC TCA GCT G_cT GCT TTC ACC AAC AAC CTC ACC
Arg Ser Asn Ser Ile Ser Ala Ala Ala Phe Phe Thr Asn Asn Leu Thr
130 135 140

T(3)

C(3)

C(3)

GTT TGC TCT GT_t CT_a CGC AAA TTC G_tC TCC GGT GAG TTT CCT CTC CCC
Val Cys Ser Val Leu Arg Lys Phe Val Ser Gly Glu Phe Pro Leu Pro
145 150 155 160

T(3)

G(3)

GCT GAT CCC GCT TCC GCG C_cG TAT CTC GTC CGT GGC TT_a CCG GCT TTG
Ala Asp Pro Ala Ser Ala Pro Tyr Leu Val Arg Gly Leu Pro Ala Leu
165 170 175

C(3)

G(3)

AGC TAC GAC GAG CTT CCT TCC TTC G_tC GG_a CGT CAC TCG TCG AGC CAC
Ser Tyr Asp Glu Leu Pro Ser Phe Val Gly Arg His Ser Ser His
180 185 190

G(4)

C(3)

AT(3) T(3)

GC_g GA_a CAC GGG AGA GTT CTT CTG AAC CAG TTC cgT AAC CA_c GAA GAT
Ala Glu His Gly Arg Val Leu Leu Asn Gln Phe Arg Asn His Glu Asp
195 200 205

G(4)

G(3)

GCT GAT TGG CTG TTC GTC AAC aGC TTC GAA GGG TTA GAG ACA CAA GGT
Ala Asp Trp Leu Phe Val Asn Ser Phe Glu Gly Leu Glu Thr Gln Gly
210 215 220

T(3) A(4)

A(3) A(3)

TGT GAA GTT GGA GAA TCA GAG gC_g ATG AgG GCG ACG TTG ATC GGA CCT
Cys Glu Val Gly Glu Ser Glu Ala Met Arg Ala Thr Leu Ile Gly Pro
225 230 235 240

C(3)	T(3)	C(3)
<u>ATG ATa CCA TCT GCT TAT CTc GAC GgC CGA ATC AAA GAC GAT AAA GGC</u>		
Met Ile Pro Ser Ala Tyr Leu Asp Gly Arg Ile Lys Asp Asp Lys Gly		
245	250	255

T(3)		
<u>TAC GGC TCG AGc CTG ATG AAG CCG CTC TCG GAG GAG TGT ATG GAG TGG</u>		
Tyr Gly Ser Ser Leu Met Lys Pro Leu Ser Glu Glu Cys Met Glu Trp		
260	265	270

T(3)		
<u>TTA GAC ACT AAG CTG AGc AAG TCG GTG GTT TTT GTT TCG TTT GGT TCC</u>		
Leu Asp Thr Lys Leu Ser Lys Ser Val Val Phe Val Ser Phe Gly Ser		
275	280	285

A(3)	A(3)	A(3) C(3)
<u>TTT gGG ATC CTC TTT GAG AAG CAA CTc GCT GAG GTg GCA AaG GCG TTA</u>		
Phe Gly Ile Leu Phe Glu Lys Gln Leu Ala Glu Val Ala Lys Ala Leu		
290	295	300

<25
<7

T(3) G(3)		
<u>CAA GAA TCC AAC TTT AAC TTC TTG TGG GTG ATc AAA GAA GCT CaT ATA</u>		
Gln Glu Ser Asn Phe Asn Phe Leu Trp Val Ile Lys Glu Ala His Ile		
305	310	315

<u>GCG AAG TTA CCA GAA GGG TTT GTG GAA GCT ACC AAA GAC AGA GCG TTG</u>		
Ala Lys Leu Pro Glu Gly Phe Val Glu Ala Thr Lys Asp Arg Ala Leu		
325	330	335

3>	A(25)
4>	G(7) T(7)
<u>CTT GTT TCT TGG TGT AAC CAG CTT GAG GTT TTA GCT CAT GtA TCg ATA</u>	
Leu Val Ser Trp Cys Asn Gln Leu Glu Val Leu Ala His Val Ser Ile	
340	345

T(7)	C(7) G(7)
<u>GGT TGc TTT TTG ACT CAC TGC GGT TGG AAC TCG ACG tTG GAA GGa TTG</u>	
Gly Cys Phe Leu Thr His Cys Gly Trp Asn Ser Thr Leu Glu Gly Leu	
355	360

G(7) G(7)

AGT TTG GGA GTT CCG ATG GTT GGT GTG CCT CAG TGG AGT GAT CAG ATG
Ser Leu Gly Val Pro Met Val Gly Val Pro Gln Trp Ser Asp Gln Met
370 375 380

AAT GAT GCT AAG TTT GTG GAG GAG GTT TGG AGA GTT GGG TAT AGA GCG
Asn Asp Ala Lys Phe Val Glu Glu Val Trp Arg Val Gly Tyr Arg Ala
385 390 395 400

T(7)

A(7)

AAq GAq GAA GCT GGG GGA GGA GTT GTG AAG AGC GAT GAG GTG GTG AGG
Lys Glu Glu Ala Gly Gly Val Val Lys Ser Asp Glu Val Val Arg
405 410 415

A(7)

A(7)

TGT TTG AqA GGA GTG ATG GAA GGA GAG AGT AGT GTG GAG ATT AGA GAq
Cys Leu Arg Gly Val Met Glu Gly Glu Ser Ser Val Glu Ile Arg Glu
420 425 430

A(7)

AGT TCT AAG AAq TGG AAA GAT TTG GCT GTG AAG GCG ATG AGT GAA GGA
Ser Ser Lys Lys Trp Lys Asp Leu Ala Val Lys Ala Met Ser Glu Gly
435 440 445

T(7) T(7)

GGA AGC TCT GAT CGG AGC ATT AAT GAG TTT GTq GAG AGT cTA GGG AAG
Gly Ser Ser Asp Arg Ser Ile Asn Glu Phe Val Glu Ser Leu Gly Lys
450 455 460

25>

7>

AAA CAT

Lys His

465



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 40 2425

DOCUMENTS CONSIDERED TO BE RELEVANT					
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)		
D,X	PLANT PHYSIOLOGY, vol. 105, 1994, pages 425-433; XP002001303 GROOTWASSINK, J.W.D., ET AL.: "Immunopurification and immunocharacterization of the glucosinolate biosynthetic enzyme thiohydroximate S-glucosyltransferase" * the whole document * ---	8	C12N15/82 C12N15/54 A01H5/00 A01H5/10		
X,L	WO-A-94 19929 (DU PONT ;DEBONTE LORIN ROGER (US); FAN ZHEGONG (US)) 15 September 1994 * The units specified in this publication for quantifying the levels of glucosinolates are assumed as micromoles per gram, based on the accepted levels of glucosinolates in Canola, see for example WO9306714 and WO9010380 * the whole document * ---	12,15, 16,18,19			
X	WO-A-93 06714 (DU PONT) 15 April 1993 * page 4, line 4 - line 22 * * page 7, line 29 - line 34 * ---	12,15, 16,18,19	C12N A01H		
A	WO-A-90 10380 (ALLELIX INC ;WONG RAYMOND S C (CA); BEVERSDORF WALLACE D (CA); CAS) 20 September 1990 * page 1, line 23 - line 32 * ---	12,15, 16,18-20			
D,A	METHODS IN PLANT BIOCHEMISTRY. CHAPTER 8, vol. 9, 1993, pages 209-237, XP000565498 POULTON, J.E., ET AL: "Glucosinolates" * the whole document * ---	1-20 -/-			
The present search report has been drawn up for all claims					
Place of search	Date of completion of the search	Examiner			
THE HAGUE	23 April 1996	Maddox, A			
CATEGORY OF CITED DOCUMENTS					
X : particularly relevant if taken alone	T : theory or principle underlying the invention				
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date				
A : technological background	D : document cited in the application				
O : non-written disclosure	L : document cited for other reasons				
P : intermediate document	& : member of the same patent family, corresponding document				



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 40 2425

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)						
D,A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, March 1994, WASHINGTON US, pages 2166-2170, XP002001305 CHAVADEJ, S., ET AL.: "Redirection of tryptophan leads to production of low indole glucosinolate canola" * the whole document *	1-20							
A	BULL. LIAISON - GROUPE POLYPHENOLS (1992), 16(PT. 2), 305-8, XP000569141 VARIN, L., ET AL.: "Expression of flavonol sulfotransferase gene in canola, potato and tobacco" * the whole document *	1-20							
A	WO-A-87 07299 (CALGENE INC) 3 December 1987 * page 10, line 3 - line 14 *	1-20							
A	WO-A-90 12084 (DNA PLANT TECHN CORP) 18 October 1990 * page 5, line 13 - page 6, line 23 *	1-20	TECHNICAL FIELDS SEARCHED (Int.Cl.6)						
A	PLANT PHYSIOLOGY, vol. 93, 1990, pages 522-524, XP002001307 LEFEBVRE, D.D.: "Expression of mammalian metallothionein suppresses gluocinolate synthesis in Brassica campestris" * the whole document *	1-20							
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>23 April 1996</td> <td>Maddox, A</td> </tr> </table>				Place of search	Date of completion of the search	Examiner	THE HAGUE	23 April 1996	Maddox, A
Place of search	Date of completion of the search	Examiner							
THE HAGUE	23 April 1996	Maddox, A							
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document							
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document									